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Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), an immunoglobulin 
family adhesion molecule, is involved in endothelial migration and angiogenesis. I found 
that PECAM-1 deficient endothelial cells exhibit enhanced nondirected single cell 
motility and extension formation at the expense of wound-healing migration. These in 
vitro endothelial behaviors model aspects of highly developmentally and 
pathophysiologically relevant processes. Wound healing migration may model the 
reendothelialization of denuded vasculature following balloon angioplasty or the 
remodeling of vascular endothelium under variant flow conditions; single cell motility is 
prominently involved in developmental processes such as endocardial-mesenchymal 
transition within the cardiac cushion. A specific deficiency of RhoGTP in PECAM-1 
deficient endothelial cells accounted for their migratory phenotype. The serum 
sphingolipid sphingosine-1-phosphate (SIP) drives Rho-dependent migration and 
angiogenesis. Indeed PECAM-1 proved necessary for an appropriate wound healing
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response to SIP. PECAM-1 localizes to rafts, and in its absence heterotrimeric G protein 
components are differentially recruited to rafts, providing a potential mechanism for 
PECAM-1-mediated coordination of SIP signaling.
PECAM-1 activates the tyrosine phosphatase SHP-2 via its phosphorylated 
immunoreceptor tyrosine-based inhibitory motif (ITIM). ITEM signaling is not required 
for the positive Rho-activating role of PECAM-1. Instead I found that ITIM signaling 
retards wound healing migration, and that during migration the second ITIM tyrosine 
becomes selectively dephosphorylated. The second ITIM tyrosine proved important for 
recruitment but not activation of SHP-2. Any SHP-2 that remains transiently associated 
with partially dephosphorylated PECAM-1 could in theory amplify the migration signal 
by dephosphorylating adjacent PECAM-1 ITIMs. PECAM-1 also helps localize SHP-2 
to the actin cytoskeleton, and to a subset of phosphoproteins. In fact, interfering with 
PECAM-1 ITIM signaling not only increased wound healing migration but decreased 
dephosphorylation of beta catenin and focal adhesion kinase. SHP-2 targeting is 
instrumental in controlling endothelial wound healing migration, potentially via effects 
on adherens junction stability and focal contact dynamics.
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Chapter 1: Background
PECAM-1 signaling in vascular biology
Platelet Endothelial Cell Adhesion Molecule-1, or PECAM-1, is a 130 kD type I 
transmembrane adhesion molecule expressed on endothelial cells, platelets, neutrophils, 
monocytes, and subsets of T cells (Albelda et al., 1991; Albelda et al., 1990; Newman et 
al., 1990). Although PECAM-1 knockout (KO) mice are viable, fertile, and overtly 
developmentally normal (Duncan et al., 1999), abnormalities of vascular functioning 
become apparent in response to certain insults. Aberrant endothelial cell-platelet 
thrombus interactions result in prolonged bleeding times attributable to endothelial rather 
than platelet dysfunction (Mahooti et al., 2000). In a murine model of multiple sclerosis 
(experimental autoimmune encephalitis) PECAM-1 KO mice exhibit neurologic deficits 
early, and infiltration of their central nervous system by mononuclear cells is similarly 
accelerated (Graesser et al., 2002). This abnormality too localizes to the vasculature 
rather than the bone marrow; indeed these mice have a defect in restoration of junctional 
integrity in response to a permeability-promoting stimulus.
In fact even angiogenesis is impaired in the PECAM-1 knockout mouse under 
certain conditions. PECAM-1 deficient endothelial cells display poor tube formation in 
three dimensional collagen culture. Moreover, a markedly diminished vascular 
infiltration into a sterile polyvynil acetate sponge is seen in the PECAM-1 knockout 
mouse during the chronic phase of a model of foreign body inflammation (Solowiej et al.,
1
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2002). PECAM-1 in fact plays multiple roles in vascular endothelial biology. Anti- 
PECAM-1 antibodies block endothelial wound healing migration, whereas expression of 
PECAM-1 mutated in its immunoreceptor tyrosine based inhibitory motif enhances 
endothelial sheet migration (Cao et al., 2002; Kim et al., 1998). Treatment with 
antibodies against PECAM-1 inhibits both endothelial tube formation and angiogenesis 
(Cao et al., 2002; DeLisser et al., 1997).
PECAM-1 has roles to play in the physiology' of established vasculature as well. 
Both anti-PECAM-1 treated wildtype endothelium and PECAM-1 deficient endothelium 
has a defect in permeability to macromolecules (Ferrero et al., 1995; Graesser et al., 
2002). PECAM-1 may even play a role in regulation of vascular tone, with endothelial 
PECAM-1 engagement mediating vasoactive mediator release, which may then act on 
subjacent vascular smooth muscle cells (Gurubhagavatula et al., 1998). In the area of 
leukocyte-endothelial interaction as well PECAM-1 has a role to play in leukocyte 
adherence to (Chiba et al., 1999; Piali et al., 1995; Tanaka et al., 1992) and 
transmigration across (Graesser et al., 2002; Gumina et al., 1996; Vaporciyan et al.,
1993) vascular endothelium.
The PECAM-1 extracellular domain consists of six immunoglobulin-like repeats 
(Figure 1) and can mediate homophilic, and perhaps heterophilic, binding interactions 
(Baldwin et al., 1994). The heterophilic binding partner for PECAM-1 remains unclear; 
after initial reports of interaction with glycosaminoglycans (Vaporciyan et al., 1993), the 
model of PECAM-1 as a heparin-binding protein has been effectively ruled out (Sun et 
al., 1998). Interaction with CD38, an adenosine diphosphate ribosyl cyclase, (Deaglio et 
al., 1998) has also been suggested, although no further work has been published to
2
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confirm this. PECAM-1 integrin heterophilic interactions, on the other hand, appear to 
be real, if  indirect; they generally involve an initial outside-in signaling step 
experimentally induced by PECAM-1 engagement accompanied by tyrosine 
phosphorylation of the cytoplasmic domain, followed by inside-out signaling in the form 
of integrin activation (increased adhesive activity). This model holds for several families 
of integrins including T cell 61 integrins (Tanaka et al., 1992), natural killer cell (52 
integrins (Berman et al., 1996), and endothelial avp3 (Chiba et al., 1999).
The cytoplasmic domain of PECAM-1 has no intrinsic enzymatic activity but 
instead associates with several signaling molecules including the tyrosine phosphatase 
SHP-2, beta catenin, gamma catenin or plakoglobin, and STAT family proteins (Figure 
1). The 106 residues of the PECAM-1 cytoplasmic domain are encoded by seven short 
exons which are alternatively spliced during development (Baldwin et al., 1994; Sheibani 
et al., 1999). Tyrosines 663 and 686 (Lu et al., 1997) in exons 13 and 14 constitute an 
ITIM, or immunoreceptor tyrosine-based inhibitory motif (Newman, 1999), which binds 
and modulates the activity of SH2-domain-containing proteins when phosphorylated 
(Pumphrey et al., 1999).
Homophilic engagement of PECAM-1 using recombinant PECAM-1 extracellular 
domain to mimic the cell-cell interactions found in confluent endothelium results in 
tyrosine phosphorylation of the PECAM-1 cytoplasmic domain (Bird et al., 1999). 
Antibody-mediated or homophilic PECAM-1 engagement independent of PECAM-1 
clustering likewise causes src-dependent PECAM-1 tyrosine phosphorylation, resulting 
in calcium influx and prostacyclin release (Gurubhagavatula et al., 1998; O'Brien et al., 
2001). PECAM-1 engagement-mediated integrin activation, on the other hand, requires
3
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concomitant PECAM-1 cis-dimerization or clustering (Leavesley et al., 1994; Tanaka et 
al., 1992; Varon et al., 1998). PECAM-1 extracellular domains have been shown to cis- 
dimerize with a dissociation constant of -12 |iM (Newton et al., 1999). Elegant studies 
manipulating PECAM-1 cytoplasmic domain oligomerization state have validated the 
model of PECAM-1-mediated inside-out signaling. Forced dimerization and 
oligomerization of the PECAM-1 cytoplasmic domain caused changes in integrin 
activation state and homophilic cell-cell adhesion (Zhao and Newman, 2001).
In addition to homophilic engagement, endothelial PECAM-1 is tyrosine 
phosphorylated in response to a number of physiologic stimuli. Increased flow and 
osmotic shock (Masuda et al., 1997); the atherosclerotic plaque component 
lysophosphatidylcholine (Ochi et al., 1998); and exposure to vascular endothelial growth 
factor (VEGF), a major angiogenic and permeability factor (Esser et al., 1998), all induce 
PECAM-1 tyrosine phosphorylation. Phosphorylation is likely mediated by Src and/or 
Csk family protein tyrosine kinases (Cao et al., 1998); in endothelial cells the protein 
tyrosine phosphatase SHP-2 is a major binding partner at the phosphorylated PECAM-1 
ITIM (Jackson et al., 1997; Masuda et al., 1997).
PECAM-1 also interacts with signaling proteins via other, as yet undefined 
portions of its cytoplasmic domain. Endothelial PECAM-1 binds two armadillo family 
proteins, beta catenin and plakoglobin, in a phosphorylation-regulated manner (Ilan et al., 
2000; Ilan et al., 1999). These intriguing signaling proteins shuttle between the plasma 
membrane, where they link adherens junctions with the actin and the intermediate 
filament cytoskeleton, respectively; the cytoplasm, where they are subject to degradation 
via the proteasome pathway; and the nucleus, where they have transcriptional regulatory
4
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effects through interactions with LEF/TCF family transcription factors (Ben-Ze'ev and 
Geiger, 1998).
PECAM-1 also binds and modulates the phosphorylation of STAT5a (Ilan et al., 
2001), a member of the family of signal transducers and activators of transcription. Like 
the catenins, these multifunctional proteins shuttle between the plasma membrane and the 
nucleus in a phosphorylation dependent manner to propagate transcriptional signals in 
response to growth factor and cytokine signaling (Pellegrini and Dusantcr-Fourt, 1997). 
In short, PECAM-1, while certainly involved in cell-cell interactions, is much more than 
a simple adhesion molecule: it is a signaling scaffold sensitive to multiple physiologic 
inputs and capable of coordinating complex endothelial behaviors.
5







)-< P Immunoreceptor Tyrosine- 
J><p based Inhibitory Motif
Figure 1: Schematic of Platelet-Endothelial Cell Adhesion Molecule-1.
Two adjacent endothelial cells with homophilically adhesive PECAM-1 molecules 
and interacting signaling proteins are depicted. (Y = tyrosine, P = phospho)
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Research Aims
• To characterize the positive role of Platelet Endothelial Cell 
Adhesion Molecule-1 in the coordinated migration of 
endothelial cells
• To elucidate the signals and signaling pathways that 
mediate this positive role
• To clarify the negative modulatory role of the PECAM-1 
immunoreceptor tyrosine-based inhibitory motif and its 
interaction with the protein tyrosine phosphatase SHP-2 in 
endothelial migration
7
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 2: PECAM-1 dependent migratory characteristics of endothelial cells
Summary
Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), an immunoglobulin 
family vascular adhesion molecule, is involved in endothelial cell migration and 
angiogenesis (DeLisser et al., 1997; Lu et al., 1996). Endothelial cells lacking PECAM-1 
expression exhibit increased single cell motility and extension formation. Their 
coordinated wound healing migration is however retarded in comparison to PECAM-1 
expressing endothelium. This migratory phenotype is reminiscent of cells in which Rho 
activity has been suppressed by overexpressing a GTPase Activating Protein (Arthur et 
al., 2000). The ability of PECAM-1 to restore wound healing migration to PECAM-1- 
deficient cells was independent of both its extracellular domain and of signaling via its 
immunoreceptor tyrosine-based inhibitory motif. PECAM-1-deficient endothelial cells 
had a selective defect in RhoGTP loading, and inhibition of Rho activity mimicked the 
PECAM-1-deficient phenotype of increased nondirected motility at the expense of 
coordinated migration.
The wound healing advantage of PECAM-1-positive endothelial cells was not 
only Rho-mediated but pertussis-toxin inhibitable. Both pertussis treatment (Lee et al., 
2000a) and inhibition of Rho-mediated signaling (Paik et al., 2001) likewise inhibits 
wound healing migration mediated by the serum sphingolipid sphingosine-1-phosphate 
(SIP), raising the question of whether PECAM-1 deficient endothelial cells would be 
impaired in their coordinated wound healing migration response to SIP. Indeed the
8
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difference in wound-healing migration between PEC AM-1 null and PECAM-l-positive 
endothelial cells is minimized in sphingolipid-depleted media; moreover PEC AM-1 null 
endothelial cells fail to increase their migration in response to SIP.
Effective SIP-mediated endothelial migration requires coordinated signaling via 
Galphai2 and Galphal3; these pathways are dysregulated in the absence of PECAM-1. 
Signaling pathways downstream of Galphai2 such as ERK and FAK are inappropriately 
activated even in non-migrating PECAIvI-i deficient endothelial ceils. Rho signaling, 
which is downstream of Galphal3, is in contrast depressed in PECAM-1 null 
endothelium. PECAM-1 localizes to caveolin-positive lipid raft domains and relative 
recruitment of Galphai2 versus Galphal3 to rafts is decreased in PECAM-1-deficient 
endothelial cells. PECAM-1 may thus support the effective SIP/RhoGTP signaling 
required for wound healing endothelial migration by allowing for the spatially directed, 
coordinated activation of Galpha signaling pathways.
9
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Introduction
PECAM-1 modulates migration in vitro and angiogenesis both in vitro and in 
vivo. Transfection of non-endothelial cells has revealed a role for PECAM-1 in 
modulating both coordinated, or wound healing, migration and single cell motility, 
although results have been cell type-dependent PECAM-1 expression for example 
inhibits coordinated migration in fibroblast (N1H/3T3) or epithelial (ECV304) cells (Kim 
et al., 1998; Schimmenti et al., 1992). In mesothelial (REN) cells PECAM-1 instead 
promotes coordinated migration and single cell motility (Cao et al., 2002). Anti- 
PEC AM-1 antibodies on the other hand block in vitro endothelial tube formation, wound 
healing and single cell motility. PECAM-1 antibody treatment also retards angiogenesis 
in multiple in vivo models, including FGF-2 (fibroblast growth factor-2) induced 
angiogenesis, comeal neovascularization and tumor angiogenesis (Cao et al., 2002; 
DeLisser et al., 1997).
The PECAM-1 knockout mouse is viable and fertile, with no evident angiogenic 
or vasculogenic abnormalities at baseline (Duncan et al., 1999). However, defects in 
angiogenesis into a polyvinyl acetate sponge are seen in a model of the chronic phase of 
foreign body inflammation in the PECAM-1 knockout mouse, and endothelial cells 
derived from the knockout mouse perform poorly in an in vitro assay of tube formation 
(Solowiej et al., 2002). At the same time some aspects of endothelial cell motility are 
enhanced in the absence of PECAM-1. In an in vitro model of cardiac cushion 
development (Bemanke and Markwald, 1982), migration of individual endocardial cells 
onto a type I collagen gel represents one step of the developmental process of epithelial-
10
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mesenchymal transition (EMT). Exposure to high glucose interferes with endocardial 
cell motility in this cardiac cushion explant model, secondary to a decrease in VEGF- 
mediated signaling in hyperglycemic cultures. Single endocardial cell motility however 
is preserved in the presence of high glucose in explants derived from the PECAM-1 
knockout mouse (Enciso et al., 2003).
Rho family small G proteins act in a coordinated manner to regulate cell 
extension formation, motility and directionality by modulating actin cytoskeletal and 
focal contact dynamics. Rac promotes formation of immature focal complexes, 
membrane ruffling, and lamellipodial extension formation. Rho then contributes to 
adhesion during migration, with maturation of focal complexes into focal contacts and 
suppression of further ruffling or focal complex formation (Nobes and Hall, 1999;
Rottner et al., 1999; Sastry and Burridge, 2000). The sequential activation of Rac and 
suppression of Rho at the leading edge of a cell to promote lamellipodial protrusion is 
followed by renewed Rho activation and firm focal contact adhesion to allow directed 
forward cell movement.
Rho family small G proteins play prominent roles in vascular physiology, which 
have recently been reviewed (van Nieuw Amerongen and van Hinsbergh, 2001). 
Rearrangement and migration of confluent bovine aortic endothelial cells (BAECs) in 
response to pulsatile flow is Rho-dependent (Yano et al., 1996), as is coordinated, wound 
healing migration of human umbilical vein endothelial cells or HUVEC (Aepfelbacher et 
al., 1997). Rho signaling is likewise required for HUVEC tube formation in vitro and 
VEGF-induced chorioallantoic membrane angiogenesis and tumor angiogenesis in vivo 
(Uchida et al., 2000). In fact therapeutic levels of HMG-CoA (3-hydroxy-3-
11
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methylglutaiyl coenzyme A) reductase inhibitors, statin compounds which interfere with 
cholesterol synthesis, block tube formation and angiogenesis by blocking the 
geranylgeranylation of Rho (Park et al., 2002a).
Sphingosine-1-phosphate (SIP) is a platelet-released lipid mediator of endothelial 
chemotaxis, wound-healing endothelial migration, angiogenesis, and vascular maturation 
(English et al., 2001). Platelets phosphorylate sphingosine and store the resulting SIP 
(Fukuhara et al., 1999). Platelet-released SIP accounts for most of the chemotactic 
activity of serum; SIP isolated from serum supports chemotaxis and FGF-2-induced 
angiogenesis (English et al., 2000) SIP signals through Endothelial Differentiation Gene 
(EDG) seven-transmembrane receptors to mediate endothelial cell migration and 
angiogenesis through heterotrimeric G-protein signaling (Lee et al., 2000a; Lee et al., 
1998; Lee et al., 1999b). SIP signaling via EDG-1 activates Galphai2, localizing and 
activating focal contact components Focal Adhesion Kinase (FAK) and src at the leading 
edge to promote lamellipodial extension formation (Rosenfeldt et al., 2001). EDG-3 
meanwhile activates Galphal3 to appropriately remodel the actin cytoskeleton and 
strengthen focal contacts via Rho signaling, allowing coordinated migration to occur 
(Buhl et al., 1995; Offermanns et al., 1997; Paik et aL, 2001).
Endothelial caveolin-rich membrane subdomains, or caveolae, represent a subset 
of low density, cholesterol-enriched lipid rafts (Sowa et al., 2001). These caveolin- 
positive rafts are enriched for certain signaling proteins, including heterotrimeric G 
proteins as well as Src family kinases and many others (Lisanti et al., 1994). Caveolin 
family proteins act as scaffolds which associate with signaling proteins and modulate 
their activity (Galbiati et al., 2001). In particular, caveolin-1 negatively regulates
12
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heterotrimeric G protein signaling by preferentially binding inactive, GDP (guanosine 
diphosphate)-bound Galpha proteins and inhibiting the GDP/GTP (guanosine 
triphosphate) exchange that would reactivate them (Li et al., 1995). EDG-1 too is 
recruited to lipid rafts in response to SIP treatment, and according to one report, EDG- 
receptor-mediated signaling may be inhibited by interaction with caveolin-1 (Igarashi and 
Michel, 2000). I have therefore examined the role of PECAM-1 in promoting S1P-EDG- 
driven coordinated wound-healing migration over nondirected motility of individual 
endothelial cells via modulation of Rho signaling.
13
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Results
Immortalized PECAM-1 deficient and reconstituted endothelial cells
In order to efficiently explore the role of PECAM-1 in endothelial migration I 
needed a model system of matched PECAM-1 null and PECAM-1 expressing endothelial 
cells that would survive through multiple passages and tolerate multiple manipulations.
It is possible to isolate primary mouse endothelial cells from PECAM-1 knockout and 
wildtype animals, but the procedure is time-consuming and difficult and the resulting 
endothelial cells last for very few passages in culture. An immortalized lung endothelial 
cell line has been derived from the PECAM-1 knockout mouse (PecamKO). This line 
has also been reconstituted with full-length PECAM-1 (PecamRC) to provide a control 
immortalized line resembling wildtype, PECAM-1 expressing endothelium (Graesser et 
al., 2002; Wong et al., 2000).
I confirmed PECAM-1 surface expression levels and maintenance of endothelial 
cell markers by fluorescence activated cell sorting (FACS) analysis (Figure 2). A mouse 
hemangioendothelioma-derived cell line (Eoma) which maintains characteristics of 
microvascular endothelial cells (Obeso et al., 1990) was used as a positive control.
FACS analysis revealed no PECAM-1 expression in PecamKO endothelial cells, as 
expected. PecamRC endothelial cells have surface levels of PECAM-1 similar to those in 
the Eoma positive control. Both PecamRC and PecamKO endothelial cell lines maintain 
expression of the endothelial marker VE-cadherin.
PecamRC endothelial cells form the cobblestone-like monolayers typical of 
endothelial cells in culture. PecamKO endothelial cells form similar tightly compact
14
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monolayers, but the cells are more spindle-shaped. Figure 3a demonstrates this 
morphology at the migrating front of a wound-healing endothelial monolayer. These 
morphologic differences are seen more clearly in individually plated cells that have been 
allowed to spread on fibronectin. Individually plated PecamKO cells form multiple 
extensions whereas PecamRC cells spread more evenly (Figure 3b). As a surrogate 
measure of extension formation or deviation from circularity, I derived theoretical radii 
(r) from the measured perimeter and the measured area, respectively, as if they had been 
perfect circles. For a perfect circle the ratio of rpenmeter to rarea will be 1.0; any deviation 
from circularity will produce higher ratios. This number is dimensionless and therefore 
independent of any variation in size between cell populations. The ratio of rpenmeter to rarea 
is in fact significantly increased in PecamKO cells, confirming the apparent increase in 
extension formation seen when cells are individually plated (Figure 4).
Given the morphological differences between PecamKO and PecamRC 
endothelial cells, I next assessed them for gross differences in actin cytoskeletal 
architecture and focal contact or adhesion formation (Figure 5). Cells were cultured on 
fibronectin-coated slides, then fixed and stained with rhodamine-conjugated phalloidin to 
visualize filamentous or F-actin and with anti-phosphopaxillin to highlight focal contacts 
and adhesions (Nakamura et al., 2000). Phalloidin staining revealed stress fibers 
throughout the cytoplasm of PecamRC cells, as compared to sparser, cortical actin bands 
in PecamKO cells. Immunostaining for phosphopaxillin revealed typical elongated focal 
adhesions in PecamRC cells; in PecamKO cells, phosphopaxillin staining prominently 
highlighted the leading edges of lamellipodial extensions, sites of newly forming focal 
complexes and contacts (Parsons et al., 2000).
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Figure 2: FACS analysis of PecamRC and PecamKO cells.
Surface expression of PECAM-1 is absent in PecamKO cells; the level of expression 
on PecamRC cells is similar to that in Eoma cells. Surface expression of endothelial 
marker VE-cadherin on both PecamRC and PecamKO cells is similar to that in 
Eoma cells, (control = secondary antibody)
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Figure 3: Morphology of PecamRC and PecamKO endothelial cells.
A. Confluent endothelial cells were scraped, then allowed to migrate for 24 hours.
B. Cells were allowed to spread for four hours, fixed and stained with crystal violet.
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Figure 4: Extension formation is increased in the absence of PECAM-1. 
Quantitation of ratios of r derived from perimeter versus r derived from area 
as a measure of the deviation from circularity confirms significantly higher 
extension formation by PecamKO cells. (* p < 0.000000005 vs RC, n = 89)
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Figure 5: Cytoskeletal and focal contact immunostaining.
Immunofluorescence demonstrates rounded cell shape and increased stress fibers in 
PecamRC cells (upper left panel, phalloidin stain) and distinct dash-like focal 
adhesion contacts with the underlying fibronectin matrix (upper right panel, anti- 
phosphopaxillin stain). PecamKO cells exhibit sparse cortical actin staining (lower 
left panel) and extensions whose leading edges are highlighted with the focal contact 
component phosphopaxillin (lower right panel).
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PECAM-1 promotes wound-healing migration over nondirected motility
I set out to address the role of PECAM-1 in two aspects of endothelial cell 
motility: the intrinsic nondirected movement of individual cells, and the coordinated 
movement of endothelial monolayers. Nondirected cell motility, or chemokinesis, was 
assessed by quantitating the cells that had reached the underside of a fibronectin-coated 8 
pm pore Transweii® membrane 2.5 hours after plating on top of the membrane. There 
was no chemotactic or haptotactic stimulus involved in this assay: the membranes were 
fibronectin coated on both sides, and no additional growth factors were added to the 
serum-containing media on either side of the membrane. Coordinated migration of 
endothelial cells was assessed using a wound-healing assay: endothelial cells were 
allowed to reach confluence on a fibronectin-coated culture dish, then scraped to leave 
alternating cell-free areas in a bull’s eye pattern. The distance migrated by the leading 
edge of monolayer cells into the scraped wound was measured after 24 hours.
Previous studies have come to conflicting conclusions about the effect of 
PECAM-1 expression on migration. Ectopic expression of PECAM-1 has been reported 
to decrease wound-healing migration in epithelial cells (Schimmenti et aL, 1992) on the 
one hand, and to increase both wound-healing and nondirected motility in mesothelial 
cells (Cao et al., 2002) on the other. In endothelial cells, where PECAM-1 expression is 
physiologic, the role of PECAM-1 in the two types of migration turns out to be 
discordant. I found that PecamKO endothelial cells have significantly enhanced 
nondirected motility (Figure 6a) but decreased wound-healing migration (Figure 6b) as 
compared to PecamRC endothelial cells.
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To rule out the possibility that decreased wound healing in PecamKO cells is 
secondary to a proliferation rather than a migration defect, the wound healing assay was 
also carried out in the presence of mitomycin C to block proliferation (Figure 6b). A 
concentration of mitomycin C that blocked the appearance of all mitotic figures as 
visualized by DAPI staining but that was minimally toxic was determined empirically 
(data not shown). Proliferation does contribute to wound healing migration, and overall 
distance migrated during mitomycin C treatment dropped by -50% for both PecamRC 
and PecamKO endothelial cells. However the differential in migration between the two 
cell types remained, implying that a proliferation defect does not account for the 
retardation of wound healing migration in PECAM-1-deficient endothelial cells.
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Figure 6: Migration characteristics of PecamKO and PecamRC cells.
A. PecamKO cells display enhanced nondirected motility through 8 pm fibronectin 
coated membranes but B. poor wound-healing migration on fibronectin in the 24 hour 
scrape assay as compared to PecamRC cells. The wound migration defect was not 
eliminated by blocking proliferation with mitomycin C (mito C). (* p < 0.0005 vs 
PecamRC; n = 8 for wound healing; n = 9 for transmigration)
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Parsing the contribution of PECAM-1 to wound healing
The PecamKO and PecamRC endothelial cells I have used to characterize the role 
of PECAM-1 in endothelial migration have been easy to work with largely because they 
are immortalized. By the same token, however, immortalization with polyoma middle T 
antigen is known to affect signaling through multiple pathways (Wagner and Risau,
1994), many of which could affect migration as well as survival and proliferation. To 
rule out the possibility that the migration differences between PecamKO and PecamRC 
were due to the interaction of PECAM-1 with ectopically expressed polyoma middle T 
antigen rather than to the expression of PECAM-1 itself, I chose to confirm our findings 
in a primary endothelial cell line.
I used antisense oligonucleotides (Baker et al., 2001) to decrease PECAM-1 
expression in human umbilical vein endothelial cells (HUVEC). Western blotting 
analysis confirmed stable depletion of PECAM-1 protein at both 24 and 48 hours in 
HUVEC treated with antisense oligonucleotide, as compared to stable PECAM-1 
expression in HUVEC treated with the scrambled oligonucleotide control (Figure 7a). 
Nondirected motility was significantly increased and wound healing migration decreased 
in PECAM-1 depleted HUVEC as opposed to control oligonucleotide treated HUVEC 
(Figure 7b), supporting the role of PECAM-1 itself in modulating endothelial migratory 
behavior. The fact that a similar phenotype was seen in primary endothelial cells derived 
from human as opposed to murine tissue, and from a macrovascular umbilical vein bed as 
opposed to a microvascular lung vascular bed, confirmed the wider applicability of the 
findings in PecamKO and PecamRC endothelial cells.
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I next set out to ascertain which domains of PECAM-1 were needed to mediate its 
positive role in wound healing migration. The effect of PECAM-1 on wound-healing 
could simply involve the ectodomain, which mediates homophilic cell-cell interactions.
It might involve outside in and inside out signaling via both the ectodomain and the 
cytoplasmic domain by modulating integrin activation, with engagement and clustering 
of the ectodomain leading to signaling via tyrosine phosphorylation of the PECAM-1 
ITiM (Chiba et al., 1999; Sun et al., 1996). The ITIM domain becomes 
dephosphorylated during wound healing migration (Lu et al., 1996) but phosphorylated 
during flow-induced rearrangement (Osawa et al., 1997), modulating binding and 
activation of SH2-domain containing proteins, and has been the principal target of studies 
of PECAM-1 mediated signaling to date. This signaling modality can be inactivated 
through site-specific mutagenesis of the tyrosines within the PECAM-1 ITIM. 
Alternately, the role of PECAM-1 in wound healing may call on neither the ITIM nor the 
ectodomain, but instead may involve signaling via other portions of the cytoplasmic 
domain and through interacting signaling proteins, known or unknown.
To determine the relative contributions of each domain of PECAM-1 to 
endothelial wound-healing migration, I expressed three different PECAM-1 constructs in 
originally PECAM-1 deficient endothelial cells. PecamKO cells were transiently 
transfected with constructs encoding either full-length, wildtype PECAM-1; wildtype 
PECAM-1 lacking its ectodomain; or PECAM-1 mutated in its ITIM domain to eliminate 
phosphorylation (Figure 8a). At 24 hours post transfection the endothelial cells were 
replated to fibronectin-coated dishes, allowed to become confluent overnight, and then 
assessed for their wound healing ability.
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Unlike control transfection with green fluorescent protein (GFP) or vascular cell 
adhesion molecule (VC AM), transfection of full-length PECAM-1 restored wound 
healing migration to PecamKO cells (Figure 8b). In fact all three PECAM-1 constructs 
were equally capable of supporting wound healing migration. Absolute rates of 
migration between transfection and nontransfection experiments are not comparable, 
since the toxicity of the transfection itself decreases wound healing migration. 
Nevertheless the degree of rescue of wound healing with any of die PEC AM-i constructs 
of -60% roughly approximates the -50% wound healing advantage of PecamRC versus 
PecamKO endothelial cells. Thus neither the ectodomain nor the intact ITIM domain is 
required to confer the PEC AM-mediated wound-healing advantage. The PECAM-1 
cytoplasmic domain itself appears to signal to modulate wound healing migration 
independent of tyrosine phosphorylation-mediated recruitment of SH2-domain containing 
proteins. Further truncation mutant transfection experiments will be necessary to localize 
the responsible portion of the PECAM-1 cytoplasmic domain.
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Figure 7: PECAM-1 expression modulates endothelial migration.
A. Antisense oligonucleotides decrease PECAM-1 expression in HUVEC as compared to 
the scrambled oligonucleotide control.
B. Antisense-treated HUVEC have significantly increased motility but decreased wound 
healing migration (* p < 0.005 vs scrambled; n = 6 for wound healing; n = 9 for motility)
26








B- Wound healing: transfections
300
•o1)
+ 2  CO
go*
S-s
*  -r *
lllll0
GFP VCAM FL 2F Tr 
PECAM-1
Figure 8: Contribution of PECAM-1 domains to wound healing.
A. The constructs used in transient transfections of PecamKO endothelial cells include 
full-length PECAM-1 (FL), PECAM-1 mutated in its ITIM domain (2F), and PECAM-1 
lacking the ectodomain (Tr).
B. Transient transfection of PecamKO with FL, 2F, and Tr PECAM-1 contstructs but not 
with GFP or VCAM restores wound healing migration to PecamKO cells.
(* p < 0.0005 vs GFP; n = 8)
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PECAM-l-nuU endothelial cells are selectively deficient in RhoGTP
PecamKO endothelial cells show pronounced extension-formation and enhanced 
nondirected motility, but blunted wound-healing migration. Lamellipodia are RacGTP- 
driven membrane extensions (Nobes and Hall, 1999) involved in initiation of cell 
motility. Endothelial wound healing in contrast is RhoGTP-mediated and is sensitive to 
inhibition of Rho signaling (Aepfel'bacher et aL, 1997). The two-sided migratory 
phenotype of PECAM-1 null endothelial cells may thus reflect an imbalance of Rho and 
Rac signaling. I used selective pulldown assays to assess levels of activated or GTP- 
bound Rho and Rac. RhoGTP was pulled down with a recombinant GST (glutathione-S- 
transferase) - Rhotekin Rho binding domain fusion protein (Ren and Schwartz, 2000). 
GST-p21 Activated Kinase (PAK) Rac binding domain fusion protein was used for 
RacGTP pulldowns (Royal et al., 2000). Glutathione agarose-bound fusion protein was 
used to selectively pull down GTP-bound Rho or Rac from whole cell lysates; the pulled 
down protein was quantitated and normalized to total G protein expression.
PecamKO endothelial cells proved to have a>  50% deficiency in RhoGTP levels 
as compared to Pecam RC endothelial cells (Figure 9a). There was by comparison no 
significant difference between the two cell types in RacGTP loading (Figure 9b). Lack 
of PECAM-1 expression in endothelial cells thus upsets the balance of small G protein 
signaling, with normal levels of Rac activation and concomitant decreased Rho signaling. 
The balance appears to tilt in favor of Rac-mediated control of actin cytoskeletal and 
focal contact dynamics, lowering the threshold for Rac-mediated extension formation and 
motility while interfering with Rho-dependent wound healing migration.
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The trio of well-studied small G proteins involved in modulation of actin 
cytoskeletal and focal contact dynamics in cell motility include not only Rho and Rac but 
also Cdc42. Cdc42 appears to cooperate with or act upstream of Rac in the initiation of 
extension formation in the form of membrane ruffling and lamellipodial protrusions 
(Clark et al., 1998; Nobes and Hall, 1999). The PAK binding domain fusion protein 
should pull down the GTP-bound form of the related small G protein Cdc42 in addition 
to GTP-bound Rac; however I was never able to detect Cdc42 in the pulldown fraction, 
whether due to the small fraction of activated Cdc42 present in these cell lysates or due to 
technical difficulties. Thus any potential additional role for Cdc42 in preferentially 
promoting extension formation in PecamKO cells in concert with Rac remains to be 
evaluated.
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Figure 9: PecamKO cells have a selective defect in RhoGTP loading.
A. Pulldowns with the recombinant RhoGTP-binding domain of Rhotekin reveal 
significantly decreased levels of RhoGTP in PecamKO cells (* p < 0.05 vs PecamRC)
B. Pulldowns with the recombinant RacGTP binding domain of PAK reveal no 
difference in RacGTP loading in PecamRC vs PecamKO cells (shown in duplicate).
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Activation of p!90RhoGAP contributes to RhoGTP deficiency
RhoGTP levels during migration are regulated by a GTPase activating protein, or 
GAP, which promotes the dephosphorylation of Rho-bound GTP to GDP and 
consequently inhibits Rho-mediated signaling. pl90RhoGAP was cloned and 
characterized as a pl20RasGAP-associated protein which colocalizes with alpha5betal 
integrin and Rho upon integrin clustering (Burbelo et al., 1995). The importance of 
pi 90RhoGAP in directed migration became evident with the generation of the 
pl90RhoGAP knockout mouse, which has a severe neural morphogenetic defect and 
excessive filamentous actin (F-actin) accumulation indicative of hyperactive RhoGTP 
signaling (Brouns et al., 2000).
pl90RhoGAP inhibits Rho signaling upon integrin engagement in a src- 
dependent manner (Arthur et aL, 2000), disinhibiting extension formation and cell 
motility (Arthur and Burridge, 2001). Figure 10a provides a schematic of src-mediated 
pi 90RhoGAP activation. Src-mediated tyrosine phosphorylation of pi 90RhoGAP 
mediates association with pl20RasGAP via its SH2 domains. This association in turn 
promotes the GTPase activity of pl90RhoGAP toward RhoGTP (Haskell et al., 2001). 
The consequent depression of local RhoGTP-mediated signaling then promotes extension 
formation and initiation of directed wound healing migration (Kulkami et al., 2000).
Low molecular weight protein tyrosine phosphatase (LMW-PTP) dephosphorylates 
pl90RhoGAP, blocking its inhibition of Rho signaling (Raugei et al., 2002).
To determine whether the low baseline levels of RhoGTP in PECAM-1 deficient 
endothelial cells are at least partly attributable to increased activation of pl90RhoGAP,
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pl20RasGAP was immunoprecipitated to determine levels and tyrosine phosphorylation 
of associated pi 90RhoGAP. Quantitation revealed significantly increased association of 
pl20RasGAP with pl90RhoGAP in PecamKO as compared to PecamRC endothelial 
cells (Figure 10b). The tyrosine phosphorylation of that associated pl90RhoGAP was 
also significantly increased. In the converse experiment immunoprecipitation of 
pl90RhoGAP also revealed increased p i90 tyrosine phosphorylation and pl20RasGAP 
association (data not shown). These findings are consistent with increased pl90RhoGAP 
activity and may in part account for the observed decrease in RhoGTP levels in 
PecamKO endothelial cells.
32
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
A.
src LMW PTPase
\  ^  












Figure 10: RhoGTP regulation by pl90RhoGAP.
A. The ability of pl90RhoGAP to inhibit Rho signaling is regulated by its tyrosine 
phosphorylation (PY) and association with pl20RasGAP.
B. Immunoprecipitation (IP) of pl20RasGAP reveals higher association with pl90 
RhoGAP (first two columns) and increased PY of that pl90RhoGAP (second two 
columns) in PecamKO cells (* p < 0.05 vs PecamRC).
33
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
RhoGTP deficiency mimics the PECAM-1 null motility phenotype
PecaxnKO endothelial cells, then, are selectively deficient in RhoGTP, and excess 
tyrosine phosphorylation of pl90RhoGAP and association with pl20RasGAP may at 
least in part account for this deficiency. Furthermore, the divergent migratory 
characteristics of PECAM-1 deficient endothelial cells, including increased extension 
formation and nondirected single ceil motility as opposed to decreased coordinated 
wound healing migration, are consistent with depressed Rho signaling, as when 
pl90RhoGAP is overexpressed (Arthur et aL, 2000). To determine whether in fact 
decreased Rho activity accounts for the migration characteristics of PecamKO endothelial 
cells, the Rho signaling pathway was blocked at the level of Rho itself and of its effector 
p i60 Rho coiled-coil kinase, or pl60ROCK, which mediates the RhoGTP-induced 
increase in stress fibers and focal adhesions (Ishizaki et al., 1997).
The C3 exoenzyme of C. botulinum (exoC3) ADP-ribosylates Rho and directly 
inhibits its activity, interfering with endothelial migration (Aepfelbacher et aL, 1997). 
ExoC3 abrogated the wound-healing advantage of PecamRC as compared to PecamKO  
endothelial cells (Figure 11a). Moreover, it actually significantly increased nondirected 
endothelial cell motility (Figure lib ). Y27632 is a synthetic inhibitor of the Rho 
effector pl60ROCK, which inhibits endothelial tube formation in vitro and angiogenesis 
in vivo (Uchida et al., 2000). Y27632 had effects similar to those of ExoC3 in PecamKO 
and PecamRC cells, with increased nondirected cell motility at the expense of diminished 
coordinated wound healing migration (Figure 12).
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PECAM-1 deficient endothelial cells exhibit increased extension formation to 
parallel their increased nondirected single cell motility. Quantitation of rpcnmeter to r ^  
ratios confirmed that extension formation was also significantly increased upon inhibition 
of Rho signaling (Figure 13a). Hence decreased basal RhoGTP levels can account for 
both the migratory and the morphologic characteristics of the PecamKO endothelial cell 
phenotype. To reaffirm that Rho signaling levels are important determinants of 
endothelial motility in general, I assessed the effect of Y27632 on primary bovine aortic 
endothelial cells (BAECs). Inhibition of pl60ROCK significantly increased both 
nondirected motility and extension formation in BAECs, confirming the general 
applicability of these findings to endothelial cell behavior (Figure 13b).
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Figure 11: Rho inhibition mimics the PecamKO migratory phenotype.
Cells were treated with exoC3 to directly inactivate Rho.
A. Wound migration was significantly inhibited and B. nondirected motility was 
significantly promoted by exoC3 treatment. (* p < 0.005 vs PecamRC control; 
n = 8 for wound healing; n = 9 for motility)
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Figure 12: pl60ROCK inhibition resembles Rho inhibition.
Cells were treated with Y27632 to inactivate pl60ROCK.
A. Wound migration was significantly inhibited and B. nondirected motility was 
significantly promoted by Y27632 treatment (* p < 0.005 vs PecamRC control; 
n = 8 for wound healing; n = 9 for motility)
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Figure 13: Rho signaling inhibits endothelial extension formation.
A. Quantitation of ratios of r derived from perimeter versus r derived from area 
as a measure of the deviation from circularity confirms that extension formation 
was significantly increased in Y27632-treated cells.
B. BAECs respond to inhibition of Rho signaling with increased nondirected motility and 
extensions. (* p < 0.005 vs untreated control; n = 9 for motility; n = 98 for extensions)
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PECAM-1 confers sensitivity of single cell motility to high glucose
Children of diabetic mothers are at increased risk for heart defects, particularly 
defects of the outflow tract and atrioventricular septum (Loffredo et al., 2001). Many of 
these can be traced to incomplete epithelial-mesenchymal transformation (EMT) within 
the endocardial cushion. Individual endocardial cells in this thickened area of the cardiac 
lube migrate down into the underlying cardiac jelly. They assume a mesenchymal 
phenotype and contribute to the incipient atrial and ventricular membranous septae and 
atrioventricular valves. In a model of EMT using the explanted murine endocardial 
cushion (Bemanke and Markwald, 1982), endocardial cells initially spread out from the 
explant as an endothelioid sheet They then disperse out over the type I collagen gel 
substrate as they take on an elongated, fibroblast-like morphology, gain expression of 
mesenchymal markers such as alpha smooth muscle actin, and lose expression of 
endothelial markers including PECAM-1.
Previous work from our lab has demonstrated that culturing endocardial cushion 
explants under conditions of increased glucose concentration, at levels similar to those 
found in poorly controlled maternal diabetes, interferes with EMT. Single cell motility is 
blocked; endocardial cells instead continue to grow out as a PECAM-1 positive, alpha 
smooth muscle actin negative endothelioid sheet. Endocardial cells originating from the 
PECAM-1 knockout mouse however are resistant to this effect: they continue to disperse 
out as individual cells even in the presence of high glucose (Enciso et a l, 2003).
PECAM-1-deficient endocardial cells, then, are resistant to inhibition of single 
cell motility by high glucose. Given our findings of increased nondirected motility in
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PECAM-1-deficient endothelial cells, I asked whether cultured endothelial cells could 
model this physiologically relevant behavior. Endothelial culture media contains 5 mM 
glucose, which approximates euglycemia. The nondirected motility of endothelial cells 
was determined in the presence of 30 mM glucose, a concentration consistent with 
poorly-controlled diabetes mellitus. I found that PecamRC endothelial cells were indeed 
retarded in their motility in the presence of high glucose as compared to a mannose 
osmotic control (Figure 14). However, as had been the case in the cardiac cushion 
culture system, the motility of PecamKO cells was unaffected by high glucose. Thus the 
behavior of endothelial cells in culture faithfully mirrors the behavior of explanted 
endocardial cushion tissue, and may provide useftd starting points for modeling complex 
vascular behaviors.
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Figure 14: PecamKO cells resist glucose-mediated retardation of motility.
On both collagen A. and on fibronectin B. endothelial cell motility is significantly 
decreased in the presence of high glucose as compared to mannose osmotic control 
(* p < 0.005 vs mannose, n = 9). PecamKO cells are resistant to the glucose effect.
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Decreased Rho signaling provides resistance to high glucose
Having determined that endothelial cell motility models the behavior of 
endocardial cells in the cardiac cushion explant assay, I determined to explore a potential 
mechanism for the resistance of PECAM-1 null endocardial cells to inhibition of their 
motility. The glucose-mediated inhibition of endocardial cell motility is attributable to 
decreased expression of Vascular Endothelial Growth Factor (VEGF). Normoglycemic 
cultures depleted of VEGF exhibit a migratory phenotype very similar to that of 
endocardial cushions cultured in the presence of high glucose. Conversely, VEGF 
supplementation is sufficient to rescue single cell motility in high glucose cardiac cushion 
cultures (Enciso et aL, 2003). The correct balance and timing of VEGF signaling appears 
to be crucial for successful endocardial cushion development: too much VEGF too early 
has likewise been shown to inhibit EMT (Dor et al., 2001).
Interestingly, VEGF-mediated endothelial motility is Rac-mediated and is 
inhibited by a constitutively-active mutant of Rho (Soga et al., 2001). I therefore 
hypothesized that the resistance of PECAM-1-deficient endocardial cells to glucose- 
mediated retardation of single cell motility is secondary to low Rho activation levels at 
baseline, with a consequent disinhibition of Rac-mediated lamellipodial extension and 
nondirected motility. To determine whether the decreased sensitivity of PECAM-1- 
deficient cells to glucose-mediated retardation could in fact be attributed to their 
decreased Rho activation at baseline, I quantitated endothelial cell motility in the 
presence of glucose plus or minus the pl60ROCK inhibitor, Y27632, to block signaling 
downstream of Rho. Indeed, concomitant treatment with Y27632 blocked the effect of
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high glucose on motility in PecamRC cells (Figure 15a). Two way analysis of variance 
(ANOVA) revealed a significant cell type by treatment effect for high glucose which was 
abrogated by inhibition of the Rho effector pathway with Y27632. The ANOCA results 
in effect confirm that the migratory response of PecamRC cells and PecamKO cells to 
high glucose is significantly different, and that this differential response requires intact 
signaling via the Rho effector pathway.
VEGF signaling in endothelial cells is mediated by Rac signaling and production 
of reactive oxygen species (ROS) (Colavitti et al., 2002). Figure 15b presents a model of 
VEGF-mediated induction of Rac-mediated motility, and inhibition of that motility by 
way of the PECAM-1-dependent stimulation of basal Rho activity. The small GTPase 
Rac contains an insert region which contributes to the production of ROS in the form of 
hydrogen peroxide (H2O2) (Deshpande et al., 2000); this region is required for 
lamellipodial induction (Kamoub et al., 2001). LMW-PTP, the low molecular weight 
protein tyrosine phosphatase which dephosphorylates pl90RhoGAP (Figure 10a), 
promotes Rho signaling by blocking the dephosphoiylation of Rho-associated GTP 
(Raugei et al., 2002). In fact overexpression of a human isozyme of LMW-PTP has been 
shown to block VEGF-mediated endothelial migration and angiogenesis (Huang et al., 
1999). LMW-PTP is physiologically inhibited by H2O2, which oxidizes two active site 
cysteine residues to form a disulfide bond (Caselli et al., 1998), providing a likely 
mechanism for local Rac-mediated inhibition of Rho signaling.
Thus VEGF-mediated signaling acts to promote extension formation and initiate 
motility by locally inhibiting RhoGTP. The major source of VEGF during endocardial 
cushion morphogenesis appears to be the layer of myocardium underlying the cardiac
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jelly (Enciso et al., 2003). This localized RhoGTP inhibition likely serves to direct 
endocardial cells down into the cardiac jelly, where they will go on to contribute to the 
incipient atrioventricular septum and valves. The low baseline levels of RhoGTP in 
PECAM-1 deficient endothelial or endocardial cells should therefore lower the barrier for 
Rac-mediated initiation of single cell motility. Lowering the threshold for motility, 
however, must by definition come at the cost of losing sensitivity to directional 
information, due to a lowered signal to noise ratio for initiation of extension formation. 
This lowering of die barrier for Rac-mediated extension formation in turn potentially 
explains the robust nondirectional single cell motility of PECAM-1 deficient cells in the 
face of decreased VEGF-Rac signaling secondary to hyperglycemia.
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Figure 15: Inhibition of Rho signaling abrogates the effect of glucose on motility.
A. Treatment with the pl60ROCK inhibitor Y27632 blocks the inhibitory effect of 
glucose on motility. Two way ANOVA reveals a significant cell type by treatment effect 
(p < 0.0005) for glucose, which is abrogated in the presence of Y27632.
B. Induction of lamellipodial extension through repression of Rho signaling.
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PECAM-1 is required for effective Galphai2-mediated signaling
SIP, a serum sphingolipid, signals through heterotrimeric G proteins associated 
with its seven-transmembrane EDG-family receptors. SIP-mediated endothelial wound- 
healing and directed migration is both Rho-dependent (Figure 11) and pertussis toxin 
(PTX) inhibitable. Pertussis toxin subunit A inhibits signaling via heterotrimeric G 
proteins by catalyzing ADP ribosyiation and inactivation of Gaiphai family subunits, 
including Galphai2, downstream of EDG-1 (Lee et al., 1996). SIP signaling via EDG-1 
and EDG-3 potentiates capillary morphogenesis, adherens junction formation, and 
angiogenesis in a Rho-dependent and pertussis toxin-inhibitable manner (Lee et al., 
1999a). SIP-induced endothelial tube formation and matrigel plug angiogenesis (Lee et 
al., 1999b) as well as wound healing migration (Lee et aL, 2000a) and directed, 
chemotactic motility (Lee et al., 2000b; Liu et al., 2001) have all been shown to be PTX- 
inhibitable as well.
SIP is one of an array of signaling molecules, including chemokines such as 
stromal derived factor-1 (SDF-1) (Salvucci et al., 2002) as well as thrombin 
(Maragoudakis et al., 2002), that promote endothelial migration and angiogenesis through 
heterotrimeric G protein signaling. Defects in heterotrimeric G protein signaling 
downstream of SIP may therefore be representative of dysfunctional responses to a broad 
array of seven-transmembrane receptor mediated signals in PECAM-1 deficient 
endothelial cells. Given the Rho-dependence of PECAM-1-mediated endothelial wound 
healing migration, I set out to see whether this effect might in part reflect modulation 
heterotrimeric G protein signaling by PECAM-1. Indeed, I found that PTX treatment
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abrogated the wound-healing advantage of PecamRC cells; no significant difference in 
distance migrated remained between PTX-treated PecamRC and PecamKO endothelial 
cells (Figure 16a). This, together with the key role of Rho signaling in the wound 
healing advantage conferred by PECAM-1, strongly implicates a dysfunction in 
heterotrimeric G protein-mediated signaling in the migratory phenotype of PECAM-1 
null endothelial cells.
PTX inhibits Gaiphai2-mediated activation of Extracellular signal Regulated 
Kinase (ERK) (Lee et al., 1996) and FAK as well as src (Liu et al., 2000; Rosenfeldt et 
al., 2001) downstream of the EDG-1 receptor (Figure 16b). To uncover potential 
disturbances in Galphai2-mediated signaling in PecamKO endothelial cells, I performed 
Western blots with phosphospecific antibodies to threonine/tyrosine phosphorylated ERK 
and to tyrosine 397-phosphorylated FAK (FAK PY397). These revealed significantly 
increased activation of both ERK signaling and of FAK PY397 in confluent PecamKO 
endothelial cells as compared to PecamRC cells (Figure 17). ERK phosphorylation is 
normally increased only at the free edge of an endothelial monolayer as a part of the 
normal migratory response to mechanical wounding (Pintucci et al., 2002). Indeed, ERK 
phosphorylation increased as expected in wounded, migrating PecamRC monolayers, 
while no further increase was observed in the already high levels of ERK activation in 
migrating PecamKO monolayers (data not shown). Inappropriate activation of FAK and 
ERK in confluent PecamKO cells indicates dysfunctional signaling in the absence of an 
appropriate migratory stimulus, and this signaling proves ineffective in coordinating 
migration of PecamKO monolayers when that wounding stimulus is actually provided.
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Figure 16: Galphai2 signaling in PECAM-1 mediated migration.
A. PTX abrogates the wound-healing advantage of PecamRC endothelial cells 
(* p < 0.005 vs control, n = 8).
B. EDG-1 receptor mediated signaling releases active GTP bound Galphai2, which 
activates ERK, FAK and src. Pertussis toxin (PTX) directly inhibits Galphai2.
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Figure 17: Increased ERK and FAK signaling in PecamKO cells.
Confluent endothelial cells were evaluated for:
A. Activated ERK (PERK) and B. FAK phosphorylated at Y397 (PFAK). Quantitation of 
PERK normalized to total ERK and PFAK normalized to total FAK revealed significantly 
increased activation of both FAK and ERK in PecamKO (* p < 0.05 vs PecamRC; n = 4).
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PECAM-1 promotes coordinated migration to sphingosine-l-phosphate
PECAM-1-mediated wound healing is Rho-dependent and sensitive to PTX, 
consistent with heterotrimeric G protein-mediated signaling such as that which occurs in 
response to sphingosine-l-phosphate (SIP). Sphingosine-l-phosphate (SIP) is a major 
serum-derived mediator of endothelial chemotaxis, wound-healing endothelial migration, 
angiogenesis, and vascular maturation (English et a l, 2001). To assess SIP-mediated 
migration, I measured wound healing in the absence of serum-derived sphingolipids, with 
physiologic levels of SIP added back, and in baseline sphingolipid-replete endothelial 
culture medium containing 10% FBS. Sphingolipid-free medium was prepared using 
FBS that had been charcoal-stripped to deplete it of sphingolipids (CS-FBS). Such 
treatment depletes SIP without significantly affecting levels of non-lipid growth factors 
such as VEGF and FGF-2 (English et aL, 2000).
Wound healing migration in sphingolipid-depleted CS-FBS medium was 
compared to migration in medium supplemented with 100 nM SIP [about half the 
concentration of SIP in normal human plasma (Yatomi et al., 1997)] as well as to 
migration in baseline sphingolipid-replete medium (Figure 18). PecamRC cells 
responded to SIP supplementation and to sphingolipid-replete medium with significantly 
increased migration, whereas PecamKO cells experienced no such increase in wound 
healing migration, whether in the presence of sphingolipids in general or SIP 
specifically. Two-way ANOVA revealed a statistically significant cell type by treatment 
effect, the difference in the response of PecamKO versus PecamRC cells to SIP. In fact
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there was even a nonsignificant decrease in migration of PecamKO cells with SIP 
supplementation and a significant decrease in wound healing in sphingolipid-replete 
media. It is tempting to speculate that this decrease may be due to the high nondirected 
motility seen in PecamKO endothelial cells; a further increase in random initiation of 
motility in response to SIP may further interfere with the coordinated, directional nature 
of wound healing migration. One would predict that while the single cell Trans well™ 
motility of PecamKO ceils may increase somewhat over an already high baseline in the 
presence of SIP, their directed motility in response to an SIP gradient would be severely 
compromised.
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Figure 18: Lack of appropriate SIP response in PecamKO cells.
Wound healing migration was assessed in sphingolipid-depleted media (CS-FBS), in 
CS-FBS supplemented with 100 nM SIP, and in non-depleted media (FBS). PecamRC 
cells had increased migration from in response to SIP or sphingolipid-replete media, 
whereas PecamKO cells had no such increase. (* p < 0.005 vs CS-FBS, n = 8). Two-way 
ANOVA reveals a significant cell type by treatment effect (F = 16.86, p < 0.000005)
52
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
PECAM-1 localizes to caveolin-positive lipid rafts
Lipid rafts are cholesterol-rich liquid-ordered subdomains within the liquid- 
disordered plasma membrane (Galbiati et aL, 2001). Such lipid raft domains have been 
found to help segregate associated proteins to the leading edge versus the rear of certain 
polarized migrating cells (Gomez-Mouton et al., 2001). A subset of lipid rafts which 
contain oligomerized caveolin-1 form small invaginations or caveolae which are 
particularly enriched in vascular endothelium. A number of signaling proteins including 
heterotrimeric G proteins, src and H-ras localize to these endothelial subdomains (Bar- 
Sagi, 2001; Lisanti et al., 1994), providing spatially localized signaling information that 
could potentially contribute to polarized cellular behaviors including migration.
Although caveolae as such are not concentrated at cell-cell junctions, caveolin-positive 
low density lipid raft domains have also been found to interact with components of 
adherens junctions (Galbiati et al., 2000), tight junctions (Nusrat et al., 2000), 
glycophosphoinositol-linked adhesion molecules (Harris and Siu, 2002), and even gap 
junctions (Schubert et al., 2002), and as such could play a role in the loosening of cell­
cell adhesions that permits coordinated migration of cells into a wound to occur.
I used sucrose density gradient fractionation to isolate the low density caveolin- 
positive lipid raft fraction of PecamRC and PecamKO endothelial cell monolayers 
(Figure 19a). Methyl B cyclodextrin (mBcd) disperses low density lipid rafts by 
depleting them of cholesterol. Treatment with mBcd eliminated the low density caveolin 
positive fraction, confirming that it consists of lipid rafts including caveolae.
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Interestingly, PECAM-1 was found to colocalize with caveolin-1 to the lipid raft fraction 
(Figure 19b); mBcd treatment also disrupted the low density fractionation of PECAM-1.
To determine whether the raft localization of PECAM-1 might relate to its role in 
promoting coordinated endothelial migration, I assessed the effect of raft disruption on 
wound healing and single cell motility. It must be stressed that the cellular effects of 
mBcd treatment are not limited to raft disruption, but that membrane cholesterol depletion 
additionally has a wide range of nonspecific effects including plasma membrane 
depolarization and a nonspecific depletion of Ca2+ stores (Pizzo et al., 2002). Thus these 
experiments are best interpreted as a way to rule out (or not) rather than a way to rule in 
(or not) the possibility of a role of raft localization of PECAM-1 in migration.
Additional complications arise from the fact that raft disruption interferes with 
multiple signaling pathways, not just those potentially associated with PECAM-1. In 
particular, mBcd disrupts the raft localization of H-ras (Bar-Sagi, 2001) and hence its 
ability to activate MEK and subsequently ERK. Treatment with 2 mM mBcd inhibits 
ERK activation in wound healing PecamRC and PecamKO endothelial cells (Figure 
20a). Treatment with 10 pm U0126, a MEK inhibitor, to inhibit ERK signaling 
confirmed its necessary role in both wound healing and single cell motility (Figure 20b), 
meaning that mBcd-induced inhibition of ERK signaling must be accounted for in the 
interpretation of raft disruption experiments.
In order to differentiate the effect of raft disruption from that of the concomitant 
inhibition of ERK signaling, endothelial cells were treated with 10 pm U0126 plus or 
minus 2 mM mBcd to eliminate ERK signaling even in the absence of raft disruption. 
Interestingly, mBcd treatment in the absence of ERK signaling decreased endothelial
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wound healing (Figure 21a) but increased single cell motility (Figure 21b). Thus the 
effect of raft disruption on endothelial migration is analogous to the inhibition of Rho 
signaling or the depletion of PECAM-1 expression of endothelial cells. (Similar results 
were also obtained in the absence of U0126 to inhibit MEK). While any experiments 
utilizing mBcd to disrupt rafts are necessarily nonspecific and may be attributable to non- 
raft-mediated effects of mBcd, these experiments at least fail to rule out the possibility 
that rafts may play a role in promoting coordinated wound healing migration, and that the 
raft localization of PECAM-1 may be pertinent to its role in mediating these effects.
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Figure 19: PECAM-1 localizes to a low density raft fraction.
A. Low density, caveolin positive lipid rafts separate from most other proteins by sucrose 
gradient fractionation. Methyl p cyclodextrin (mpcd) disrupts lipid rafts and disperses 
the low density caveolin positive fraction.
B. PECAM-1 cofractionates with lipid rafts in PecamRCcells, and disappears from the 
low density fraction upon raft disruption.
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Figure 20: ERK signaling supports both motility and wound healing:
A. Raft disruption interrupts ERK signaling in wound healing endothelial cells.
B. Treatment with the MEK inhibitor U0126 at 10 pm to suppress ERK activation 
interferes with both single cell and wound healing motility in PecamRC and PecamKO 
cells, (n = 16 for wound healing, n = 9 for motility; *p < 0.005)
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Figure 21: Methyl B cyclodextrin inhibits wound healing and increases motility.
Cells were pretreated with U0126 to block ERK activation independent of raft disruption; 
the effect of mBcd treatment and raft disruption on wound healing migration was evaluated.
A. Wound healing migration decreases significantly upon mBcd treatment.
(n = 8, *p < 0.05 vs U0126 alone)
B. Single cell motility increases upon m(kd treatment (n = 9, *p < 0.05 vs U0126 alone).
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PECAM-1 modulates the relative recruitment of Galphai2 and Galphal3 to rafts
PEC AM-1 cofractionates with low density caveolin-positive lipid rafts, and raft 
integrity promotes coordinated wound healing migration over nondirected single cell 
motility. PECAM-1 expression is needed for an effective coordinated migration response 
to SIP. Galpha subunits also localize to low density lipid rafts and move in and out of 
caveolae (Oh and Schnitzer, 2001). Caveoiin-1 interactions may modulate heterotrimeric 
G protein signaling: either directly by binding the inactive, GDP-bound version of 
Galpha heterotrimeric protein subunits and inhibiting GDP/GTP exchange (Li et al., 
1995), or indirectly by transiently sequestering dissociated Galpha subunits, desensitizing 
signaling via heterologous seven transmembrane receptors that share the same G protein 
(Murthy and Makhlouf, 2000). Finally, overexpression experiments in several non- 
endothelial cell lines have demonstrated that EDG-1 localizes to caveolin-positive low 
density lipid rafts (Igarashi and Michel, 2000), a process that is required for ligand- 
induced receptor internalization and resensitization (Kohno et al., 2002). Therefore the 
relative recruitment of Galpha subunits to caveolin positive rafts, and their accessibility 
to either EDG family receptors or to inhibitory associations with caveolin-1, may have a 
direct bearing on Galpha subunit localization and degree of activation.
SIP-mediated migration has a pertussis-inhibitable, EDG-1/Galphai2 mediated 
component which results in activation of ERK signaling and FAK phosphorylation, and 
an EDG-3 mediated component that couples to Galphal3, contributing to Rho activation. 
The ERK, FAK, and Rho signaling characteristics of PecamKO as compared to those of 
PecamRC endothelial cells suggest a model in which the Galphai2-mediated signal is
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promiscuously activated, and the Galphal3 component is defective, in the absence of 
PECAM-1. Given the potential role of raft localization in modulating heterotrimeric G 
protein mediated signaling, I assessed the relative targeting of Galphai2 versus Galphal3 
to rafts in PecamRC versus PecamKO endothelial cells (Figure 22a). The results of 
these preliminary experiments were consistent with a role for PECAM-1 in supporting 
the targeting of Galpha subunits to lipid rafts: the ratio of Galphai2 to Galphal3 in the 
low density caveolin positive fraction was decreased by more than naif in PecamKO as 
compared to PecamRC endothelial cells (Figure 22b).
To begin to explore how the raft localization of PECAM-1 may contribute to 
Galpha mediated Rho signaling, I assessed the tyrosine phosphorylation of pl20RasGAP 
-associated pl90RhoGAP in PecamRC and PecamKO endothelial cells that had been 
treated with mficd to disperse rafts (Figure 23a). PecamKO endothelial cells have 
increased levels of pl90RhoGAP tyrosine phosphorylation and pl20RasGAP association 
at baseline, which should in turn promote pl90RhoGAP activation, and therefore likely 
contributes to the low baseline RhoGTP levels in the absence of PECAM-1 (Figure 10). 
Raft dispersion (mficd treatment) increased pl20RasGAP-associated pl90RhoGAP 
tyrosine phosphorylation in PecamRC endothelial cells to levels similar to those seen in 
PecamKO cells (Figure 23b). Cholesterol depletion via mficd treatment is a fairly 
nonspecific treatment, as discussed in the preceding section. Nevertheless, it should 
prove fruitful to explore the potential role of PECAM-1 in promoting Galphai2-mediated 
src activation and pl90RhoGAP tyrosine phosphorylation.
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Figure 22: PECAM-1 modulates raft recruitment of Galpha subunits.
A. Western blots demonstrate raft localization of Galphai2 and Galphal3 subunits.
B. Quantitation reveals higher ratio of Galphai2:Galphal3 in the presence of PECAM-1 
(n = 4, *p < 0.05).
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Figure 23: Methyl B cyclodextrin treatment increases pl90RhoGAP PY.
A. Western blot showing tyrosine phosphorylation of pl90RhoGAP coprecipitating 
with pl20RasGAP.
B. Quantitation reveals significant increase in pl90RhoGAP PY in response to m|3cd 
treatment in PecamRC cells, to levels comparable to PecamKO cells.
(n = 2, *p < 0.05 vs PecamRC)
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Discussion
The data presented above suggest a significant new role for PECAM-1 in 
balancing coordinated wound healing migration and nondirected motility of endothelial 
cells. The PECAM-1 knockout mouse is overtly developmentally normal, but 
abnormalities of endothelial function become apparent in response to appropriate insult 
During the chronic phase of foreign body inflammation, for example, angiogenesis is 
severely compromised in the PECAM-1 knockout mouse (Solowiej et al., 2002). An in 
vitro model of angiogenesis likewise reveals a prominent defect in tube formation in 
immortalized lung endothelial cells derived from the PECAM-1 knockout mouse 
(Solowiej et aL, 2002). Embryonic endocardial cells derived from the cardiac cushion of 
the PECAM-1 knockout mouse, on the other hand, are aberrantly resistant to glucose- 
mediated inhibition of VEGF-induced scattering motility (Enciso et al., 2003). PECAM- 
1 deficient endothelial cells, then, are on the one hand defective in forming a stable new 
vasculature, and conversely are resistant to inhibition of endocardial cell motility.
Consistent with their dichotomous migratory behavior in vivo, PecamKO 
endothelial cells exhibit enhanced nondirected single cell motility and lamellipodial 
extension formation at the expense of wound-healing migration. The contribution of 
PECAM-1 to this migratory phenotype was confirmed by depleting PECAM-1 in primary 
endothelial cells using antisense technology. The migratory differences are accounted for 
by a selective deficiency of RhoGTP as opposed to RacGTP in PecamKO cells, since 
inhibition of either Rho itself or the Rho effector pl60ROCK reproduced the PECAM-1- 
deficient migratory phenotype.
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The decrease in RhoGTP loading could be at least partially attributed to increased 
activation of pl90RhoGAP, a GTPase activating protein, as marked by tyrosine 
phosphorylation and association of pl90RhoGAP with pl20RasGAP. Figure 24a 
delineates growth factor and integrin engagement-mediated lamellipodial extension and 
initiation of motility: some growth factors such as VEGF (Soga et al., 2001) activate Rac, 
which itself inhibits Rho (Sander et al., 1999); other growth factors (Haskell et al., 2001) 
and integrins (Arthur et al., 2000) activate src family kinases which phosphorylate and 
activate pl90RhoGAP, inhibiting Rho indirectly. In fact, overexpression of 
pl90RhoGAP alone derepresses Rac-mediated lamellipodial extension formation and 
enhances motility (Arthur et al., 2000). The insensitivity of PECAM-1-deficient 
endocardial cells to glucose-mediated suppression of VEGF-induced motility may thus be 
attributable to baseline low RhoGTP. In fact, like primary PECAM-1-deficient 
endocardial cells, PecamKO endothelial cells are resistant to glucose-mediated inhibition 
of single cell motility; pretreatment with an inhibitor of the Rho effector pl60ROCK 
abrogates the inhibitory effect of glucose on PecamRC endothelial cell motility.
SIP is a major endothelial chemotactic component of serum which engages EDG- 
1 and EDG-3 seven-transmembrane receptors to mediate endothelial migration and 
angiogenesis (Lee et al., 1999a; Lee et al., 1998) via downstream signaling through 
Galphai2 to FAK, ERK, and src (Lee et al., 1999b; Rosenfeldt et al., 2001) and through 
Galphal3 to Rho (Figure 24b) (Buhl et al., 1995; Offermanns et al., 1997). The wound- 
healing advantage of PecamRC cells is not only Rho-dependent but PTX-inhibitable, a 
pattern characteristic of heterotrimeric G protein-mediated endothelial migration such as 
that mediated by SIP. Physiologic levels of SIP increase wound healing migration of
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PecamRC endothelial cells, as expected; PecamKO endothelial cells in contrast are not 
responsive to SIP. Indeed the relative wound-healing advantage of PecamRC cells is 
much decreased in sphingolipid-depleted serum, implicating the heterotrimeric G protein- 
mediated sphingolipid signaling pathway in the promotion of wound healing migration 
by PEC AM-1. Elevated threonine/tyrosine phosphorylation of ERK and tyrosine 
phosphorylation of FAK in confluent PecamKO cells is consistent with dysregulated and 
ineffective Gaiphai2 signaling downstream of EDG-1 receptor. Src activity is also likely 
increased in PecamKO cells: increased FAK at PY397 indicates that more src is likely 
bound and activated at focal contacts (Eide et al., 1995); and tyrosine phosphorylation of 
pl90RhoGAP, which is also increased, is likewise mediated by src (Arthur et al., 2000).
Global activation of these pathways in and of itself is insufficient to permit 
directed migration and coordinated wound-healing. EDG-1 null fibroblasts, like 
PecamKO endothelial cells, display aberrant FAK and src activation but a decreased 
wound healing response to SIP; local FAK and src activation at the leading edge 
promotes the directed extension formation and migration of wildtype fibroblasts in 
response to SIP (Rosenfeldt et al., 2001). Interestingly, another immunoglobulin family 
molecule containing ITIM sequences in its cytoplasmic domains, SHPS-1, may play a 
similar role to that of PECAM-1 in fibroblasts: expression of SHPS-1 lacking its 
cytoplasmic domain in fibroblasts blocks RhoGTP activation and wound healing 
migration, promotes extension formation, and increases ERK and FAK phosphorylation 
(Inagaki et al., 2000).
A model of defective sphingosine-1-phosphate-mediated signaling and Rho 
activation in PECAM-1-deficient endothelial cells incorporates these observations
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(Figure 24b,c). In PECAM-1-positive endothelial cells SIP signals through Galphai2 
and Galphal3 in a coordinated maimer to produce directed extension formation and 
directed wound healing migration rather than nondirected motility (Figure 24b). In 
PECAM-1-deficient endothelial cells EDG-1 and Galphai2 are activated in a non­
coordinated manner, leading to baseline activation of ERK, FAK, and src (Figure 24c). 
Phosphorylation activates pl90RhoGAP and suppresses RhoGTP; EDG-3-mediated 
signaling to Gaiphal3 is insufficient to activate Rho, favoring extension formation and 
nondirected motility over directed wound healing migration. This lack of coordinated 
responsiveness to serum sphingolipid chemotactic signals may account for the poor 
angiogenesis into polyvinyl acetate sponge implants in the PECAM-1 knockout mouse in 
a model of the chronic phase of foreign body inflammation (Solowiej et al., 2002). 
PECAM-1 modulates the selective recruitment of Galphai2 versus Galphal3 to caveolin 
positive low density lipid raft fractions, where their activity might be modulated via 
association with EDG receptors and with caveolin-1. It will be rewarding to investigate 
the circumstances under which PECAM-1-mediated modulation of heterotrimeric G- 
protein signaling to Rho family small G proteins becomes pathophysiologically relevant.
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Figure 24: Model for role of PECAM-1 in endothelial motility.
A. Growth factor or integrin signaling coordinately activates Rac and inhibits Rho via src 
mediated phosphorylation of pl90RhoGAP, allowing lamellipodial extension and motility.
B. In PECAM-positive cells SIP signals in a coordinated manner to produce directed 
extension formation and wound healing rather than nondirected motility.
C. In PECAM-null endothelium noncoordinated EDG receptor signaling favors extension 
formation and nondirected motility over directed wound healing.
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Chapter 3: The PECAM-1 ITIM in endothelial wound healing migration
Summary
Platelet-Endothelial Cell Adhesion Molecule-1, PECAM-1, a transmembrane 
endothelial adhesion protein, binds and activates the tyrosine phosphatase SHP-2 via 
pnospnotyrosines 663 and 686. PECAM-1 phosphorylation and recruitment of SHP-2 is 
regulated by cell-cell and cell-substrate adhesion. PECAM-1 is dephosphorylated on 
tyrosine 686 during endothelial migration, resulting in diffuse dispersal of PECAM-1 and 
SHP-2. Overexpression of native PECAM-1 slowed, and nonphosphorylatable PECAM- 
1 increased, endothelial migration, implying that the SHP-2-regulatory phosphotyrosines 
negatively regulate migration. Using differentially phosphorylated recombinant proteins 
I found that phosphotyrosine 686 preferentially mediates binding and 663 mediates 
activation of SHP-2 by PECAM-1. In PECAM-1-null endothelial cells, SHP-2 bound 
and dephosphorylated an alternative set of phosphoproteins and its distribution to a 
Triton-insoluble, likely cytoskeletal fraction was significantly decreased. Tyrosine 
phosphorylation of beta catenin and focal adhesion kinase was increased in endothelial 
cells overexpressing nonphosphorylateable PECAM-1. Thus homophilically engaged, 
tyrosine-phosphorylated PECAM-1 locally activates SHP-2 at cell-cell junctions; with 
disruption of the endothelial monolayer, selective dephosphorylation of PECAM-1 leads 
to redistribution of SHP-2 and pro-migratory changes in phosphorylation of cytoskeletal 
and focal contact components.
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Introduction
Platelet-Endothelial Cell Adhesion Molecule, or PECAM-1, is a homophilically 
adhesive transmembrane glycoprotein (Albelda et al., 1990; Newman et al., 1990) which 
modulates endothelial migration, tube formation, and angiogenesis in vivo and in vitro 
(Cao et al., 2002; DeLisser et al., 1997; Kim et al., 1998). Many of these functions 
localize to the Immunoreceptor Tyrosine-based Inhibitory Motif or ITIM (Newman, 
1999), which binds and activates SH2-domain-containing proteins (Pumphrey et al.,
1999). A model of the PECAM-1 ITIM seen in Figure 25a shows the orientation of 
ITIM tyrosines 663 and 686 within a bend in the cytoplasmic domain (Kim et al., 1998). 
ITIM tyrosine 686 is dephosphorylated in endothelial cells upon engagement of 1 
integrins (Lu et al., 1996) and during normal yolk sac vasculogenesis (Pinter et al., 1997); 
dephosphorylation is abrogated during abnormal vasculogenesis in glucose-induced 
embryopathy (Pinter et al., 1999). Conversely, PECAM-1 mutated at tyrosine 686 
increases endothelial wound healing migration (Kim et al., 1998). PECAM-1 
phosphorylation at tyrosine 686 also increases homophilic cell-cell adhesion, supporting 
a role for the ITIM in inside-out signaling (Famiglietti et al., 1997; Yan et al., 1995)
In endothelial cells the tyrosine phosphatase SHP-2 is a major PECAM-1 ITIM 
partner (Jackson et al., 1997; Masuda et al., 1997). SHP-2 was identified as a homologue 
of a Drosophila gene, csw, involved in early development downstream of a receptor 
tyrosine kinase (Freeman et al., 1992). It is a ubiquitously-expressed protein tyrosine 
phosphatase which is activated by occupancy of its two tandem SH2 domains (Dechert et 
al., 1994; Sugimoto et al., 1993). The crystal structure of SHP-2 (Figure 26a) has
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revealed that a portion of the N-terminal SH2 domain (N-SH2) sterically blocks access to 
the active site (Barford and Neel, 1998). Phosphotyrosine engagement of the N-SH2 
domain shifts it out of the active site, sterically activating the en2yme (Hof et al., 1998). 
Engagement of the C-terminal SH2 domain contributes to binding specificity of 
appropriately spaced phosphotyrosines, but does not contribute to enzyme activation.
The spacing of the SH2 domains of SHP-2 (Eck et al., 1996) confers on it high specificity 
for engagement by the tandem phosphotyrosines located in ITIMs (Ottinger et al., 1998), 
including that of PECAM-1 (Jackson et al., 1997), as opposed to the more closely spaced 
bisphosphorylated ITAMs (immunoreceptor tyrosine-based activation motifs) (Ottinger 
et al., 1998). Thus the phosphorylation of one or both PECAM-1 ITIM tyrosines may be 
expected to have differential effects both on SHP-2 recruitment and on modulation of its 
tyrosine phosphatase activity.
Coordinated migration of endothelial cell monolayers involves loosening of 
adherens junctions and focal contact turnover. Vascular endothelial cadherin (VE- 
cadherin) plays a large role in maintaining tight endothelial cell-cell interactions at 
adherens junctions (Corada et al., 1999). These junctions undergo major reorganization 
at the migrating front of a wounded endothelial monolayer (Lampugnani et al., 1995). 
Beta catenin becomes tyrosine phosphorylated in response to stimuli that induce an 
increase in vascular permeability and angiogenesis, such as vascular endothelial growth 
factor or VEGF (Cohen et al., 1999). Linkage of VE-cadherin to the actin cytoskeleton 
via beta catenin association with alpha catenin (Provost and Rimm, 1999), and hence the 
stability of cadherin-mediated cell-cell adhesion, is regulated by beta catenin tyrosine 
phosphorylation (Ukropec et al., 2002).
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A number of protein tyrosine phosphatases, including LMW-PTPase (Taddei et 
al., 2002), RPTPase (receptor-type protein tyrosine phosphatase) beta/zeta (Meng et al.,
2000), PTP1B (Balsamo et al., 1998), and PTP-LAR (leukocyte common antigen related) 
have been implicated in the maintenance of cadherin-mediated cell-cell adhesion through 
dephosphorylation of beta catenin by overexpression in non-endothelial cells. In 
endothelial cells, and in the absence of overexpression, SHP-2 is the only protein tyrosine 
phosphatase that has been implicated in beta catenin dephosphorylation. Endothelial 
PECAM-1 binds tyrosyl-phosphorylated beta catenin (Ilan et al., 1999); beta catenin is 
therefore in a position to be targeted for dephosphorylation by PECAM-1 ITIM activated 
SHP-2. Although no direct evidence of SHP-2-mediated dephosphorylation of beta 
catenin is available, the loss of SHP-2 from adherens junction complexes in response to 
thrombin (Ukropec et al., 2000) or shear stress (Ukropec et al., 2002) correlates with 
increased beta catenin phosphorylation and loss of cadherin-cytoskeletal linkage.
Focal adhesion kinase (FAK) activity, mediated by autophosphorylation (Owen et 
al., 1999), is also required for migration (Gilmore and Romer, 1996). SHP-2 modulates 
tyrosine phosphorylation of FAK and thus focal contact turnover and cell motility 
(Gilmore and Romer, 1996; Yu et al., 1998), and FAK tyrsoine phosphorylation is 
increased in PECAM-1 deficient endothelial cells (Figure 17b), providing another 
potential target for PECAM-1 ITIM-associated SHP-2 dephosphorylation. The 
functional role of PECAM-1-mediated modulation of SHP-2 tyrosine phosphatase 
activity in endothelial cell migration however remains unclear. To this end I studied the 
role of the PECAM-1 ITIM in migration-related SHP-2 recruitment and activation, and 
the dephosphorylation of potential target phosphoproteins relevant to migration.
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Figure 25: A model of the PECAM-1 ITIM.
A. A model of the PECAM ITIM reveals a loop in the cytoplasmic domain which makes 
tyrosines 663 and 686 readily available for phosphorylation
(Kim C.S. et al, Lab Invest. 78:583,1998).
B. The PECAM-1 cytoplasmic domain was as a GST fusion protein; the ITIM tyrosines 
were individually mutated to allow for selective phosphorylation.
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Figure 26: Recombinant SHP-2 production.
A. Model derived from crystal structure of SHP-2 (Hof P. et al, Cell 92:441 (1998). 
N-SH2 domain moves out of catalytic cleft upon PY engagement (C = catalytic cysteine)
B. GST-SHP-2 was captured on glutathione beads, then thrombin-cleaved to remove GST.
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Results
SHP-2 is preferentially bound by PECAM-1 phosphotyrosine 686
The PECAM-1 cytoplasmic domain was expressed as a fusion protein, with 
glutathione-S-transferase at its N-terminal (Lu et al., 1997) allowing ease of purification 
using glutathione agarose beads. GST-PECAM-i containing site-directed mutations at 
tyrosines 663 and 686 of the ITIM was produced in bacteria expressing a kinase capable 
of phosphorylating available tyrosines (Figure 25b). Western blotting with 
phosphospecific antibodies (Figure 27a) (Lu et al., 1996) confirmed site-specific tyrosine 
phosphorylation. Recombinant SHP-2 (rSHP-2) was cleaved from its GST tag at an N- 
terminal thrombin cleavage site (Figure 26b). Pulldown assays using GST-PECAM-1 
assessed the contribution of the respective ITIM phosphotyrosines to SHP-2 recruitment 
(Figure 27b). PECAM-1 phosphorylated only at tyrosine 686 pulled down the same 
amount of SHP-2 as dually phosphorylated PECAM-1; lack of phosphorylation at 686 
however significantly decreased SHP-2 binding. Thus both ITIM tyrosines are capable 
of binding SHP-2, but loss of phosphorylation at tyrosine 686 would likely lead to a 
significant decrease in PECAM-1-associated SHP-2.
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Figure 27: Contribution of HIM tyrosines to SHP-2 binding.
A. GST-PECAM-1 phosphorylation was confirmed with phosphospecific antibodies.
B. Pulldown assay using phosphorylated GST-PECAM-1 as bait 663F-PY pulls down as much 
SHP-2 as PEC-PY, but 686F-PY pulls down significantly less, (n = 5, *p < 0.005 vs PEC-PY).
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PECAM-1 phosphotyrosine 663 preferentially activates SHP-2
Engagement of the SH2 domains of SHP-2 serves not only to recruit the 
phosphatase but to activate it (Barford and Neel, 1998; Dechert et al., 1994). All reports 
of PECAM-l-mediated SHP-2 activation thus far have used phosphorylated peptides 
(Pluskey et al., 1995). However, the secondary and tertiary structure of the PECAM-1 
cytoplasmic domain may have profound effects on SHP-2 binding and activation. I 
measured SHP-2 activity by monitoring dephosphorylation of the synthetic substrate 
pNPP (p nitrophenyl phosphate). Recombinant SHP-2 (rSHP-2) had a baseline activity 
of 15 nM pNP /minute, while rSHP-2 mutated in its catalytic acid (Flint et al., 1997) was 
inactive as expected (Figure 28a). The responsiveness of rSHP-2 to engagement of its 
SH2 domains was tested using ITIM phosphopeptides. Phosphopeptide 663 produced a 
dose-dependent increase in SHP-2 activity, while the same peptide in nonphosphorylated 
form produced no increase in phosphatase activity over baseline (Figure 28b).
The relative role of the two ITIM phosphotyrosines was then tested using 
phosphopeptides: while phosphopeptide 663 activated rSHP-2 in a dose-dependent 
manner, neither nonphosphorylated 663 nor phosphopeptide 686 did so (Figure 29a). 
Activation was then tested in the context of the full PECAM-1 cytoplasmic domain 
(Figure 29b). PECAM-1 phosphorylated at 663 alone activated SHP-2 as well as dually 
phosphorylated PECAM-1, whereas PECAM-1 phosphorylated at 686 caused very little 
activation over baseline. Thus the two individual phosphotyrosines of the PECAM-1 
ITIM play individual and complementary roles in modulation of SHP-2 activity, with 
phosphotyrosine (PY) 686 recruiting and PY 663 activating the phosphatase.
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Figure 28: Assessment of recombinant SHP-2 phosphatase activity.
Phosphatase activity was measured using p-nitrophenyl phosphate (pNPP) as substrate.
A. rSHP-2 dephosphorylates pNP at 15 nM/min at baseline; a loss of function mutant 
(D425A) is inactive (n = 5, *p < 0.005).
B. Stimulation of SHP-2 activity by phosphorylated (663-PY) vs nonphosphorylated 
(663-Y) ITIM phosphopeptide.
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Figure 29: SHP-2 is preferentially activated by PY 663.
A. Phosphopeptides 663-PY but not 663-Y or 686-PY stimulate rSHP-2 activity in a dose 
dependent manner.
B. Stimulation of rSHP2 activity by rPECAM-1. PECAM-1 phosphorylated at both ITIM 
tyrosines (PEC-PY) or at 663 alone (686F-PY) but not 686 alone (663F-PY) significantly 
activated SHP-2 (n = 6, *p < 0.005).
78
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The PECAM-1 ITIM is selectively dephosphorylated during migration
PECAM-1 localizes to cell-cell contacts in confluent endothelial cells (Albelda et 
al., 1990); homophilically-engaged PECAM-1 is tyrosine-phosphorylated and able to 
bind SHP-2 (Bird et al., 1999). Accordingly PECAM-1 and SHP-2 co-localized to cell­
cell borders of confluent human umbilical vein endothelial cells, whereas migrating cells 
displayed diffuse PECAM-1 and SHP-2 staining (Figure 30). Previous work from our 
laboratory has evaluated the relative phosphorylation of each of the PECAM-1 ITIM 
phosphotyrosines during migration (Gratzinger et al., 2003a). To assess PECAM-1 PY 
during migration, confluent bovine aortic endothelial cells (BAECs) were wounded by 
mechanical scraping. The remaining concentric circles of migrating endothelium were 
evaluated at 24 hours post wounding; by 72 hours, they had reachieved confluence. 
Immunoprecipitation revealed decreased total PECAM-1 PY, and consequently SHP-2 
association, in migrating BAECs 24 hours post-wounding; at 72 hours, the newly 
confluent BAECs reachieved baseline PECAM-1 PY (Figure 31a). Analysis with 
phosphospecific antibodies revealed that relative dephosphorylation at tyrosine 686 
(74%) was much greater than that at tyrosine 663 (21%) (Figure 31b). Thus, 
dephosphorylation of the PECAM-1 ITIM during migration occurs preferentially at the 
site that recombinant protein pulldown experiments implicate in recruiting SHP-2.
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confluent migrating
Figure 30: Colocalization of SHP-2 and PECAM-1.
Immunofluorescence reveals cell-cell border localization of both PECAM-1 (upper) and 
SHP-2 (middle) in confluent human umbilical vein endothelial cells; colocalization is 
shown at bottom. In migrating cells, PECAM-1 and SHP-2 are both diffusely localized.
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Figure 31: Preferential dephosphorylation at Y686 during migration.
A. Immimoprecipitation of PECAM-1 reveals decreased PY and SHP-2 association in 
migrating BAECs. Quantitation reveals a > 50% decrease in PECAM-1 PY at 24 hours 
wound healing, with baseline PY restored at confluence (72 hr) (n = 3, *p < 0.05 vs 0 hr).
B. Blotting with phosphospecific antibodies to the PECAM-1 ITIM reveals greater 
dephosphorylation at Y686 than at 663 (n = 2, *p < 0.05 vs total PY).
(Work of M. Barreuther (D. Gratzinger, M. Barreuther, J.A. Madri,unpublished data).
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PECAM-1 expression localizes SHP-2 to a Triton-insoluble fraction
Immortalized lung endothelial cells derived from the PECAM-1 knockout mouse 
(PecamKO) and reconstituted with full-length PECAM-1 (PecamRC) form contact- 
inhibited confluent monolayers and maintain expression of endothelial markers such as 
VE-cadherin (Graesser et al., 2002; Wong et al., 2000). To evaluate the role of PECAM- 
1 in localizing SHP-2 to potential target pnosphoproteins, i assessed the relative 
recruitment of SHP-2 to a Triton X-l 00 insoluble fraction. Less than half as much SHP-2 
was found in the Triton-insoluble pellet in PecamKO as PecamRC endothelial cells;
Focal Adhesion Kinase (FAK) was by comparison found in comparable amounts 
regardless of endothelial PECAM-1 expression status (Figure 32a). The Triton-insoluble 
pellet represents cytoskeleton-associated proteins, but lipid raft components are also 
Triton-insoluble. Sucrose density gradient fractionation of the low-density, caveolin- 
positive lipid raft fraction (Sowa et al., 2001) however failed to demonstrate any 
significant partitioning of SHP-2 to rafts in either PecamKO or PecamRC endothelial 
cells (Figure 32b); SHP-2 instead localized to the higher density fractions along with 
beta actin.
The fact that PECAM-1 dependent SHP-2 partitioning to a Triton-insoluble 
fraction appears cytoskeletal rather than raft-associated despite the large fraction of 
PECAM-1 that fractionates in a low-density caveolin positive fraction (Figure 19) 
requires further clarification. Several possibilities exist: one, that PECAM-1-associated 
SHP-2 becomes dissociated at some point during the raft preparation process; two, that 
SHP-2 largely associates with that fraction of PECAM-1 that is not localized to lipid
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rafts; three, that SHP-2 is simultaneously raft and cytoskeletally associated, but 
fractionates with the cytoskeleton thanks to the properties of the separation technique; 
and four, that the change in SHP-2 localization is due not only to direct co-localization of 
SHP-2 with tyrosyl-phosphorylated PECAM-1, but to consequent changes in tyrosine 
phosphorylation of other SHP-2 target proteins which likewise provide sites for SHP-2 
binding contribute to the relocalization of SHP-2. A combination of alternate 
biochemical methods of raft separation and immunostaining of intact cells should help to 
clarify these issues.
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Figure 32: PECAM-1 modulates subcellular distribution of SHP-2.
Levels of SHP-2 and FAK in the Triton-insoluble pellet were normalized to actin.
A. PecamKO cells have significantly lower levels of SHP-2 but not FAK in the 
Triton X-100 insoluble fraction (n = 6, *p < 0.05 vs PecamRC).
B. Sucrose density gradient fractionation separates caveolin-postive lipid rafts 
(fractions 3-4) from nonraft proteins in p actin-positive fractions 9-11; SHP-2 is 
not present in rafts in PecamRC or PecamKO endothelial cells.
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SHP-2 binds alternate target proteins in the absence of PEC AM-1
In the absence of PECAM-1, SHP-2 is inefficiently localized to a Triton-insoluble 
fraction (likely cytoskeletal), and consequently likely has access to an alternate set of 
target phosphoproteins. To test this hypothesis I immunoprecipitated SHP-2 from 
PecamKO and PecamRC endothelial cells and evaluated for co-precipitating tyrosyl 
phosphorylated proteins. SHP-2 from PecamRC and PecamKO endothelial cells 
consistently co-precipitated different phosphoproteins. The major bands were of 
apparent molecular weight ~125kD and 140kD, respectively, in PecamRC and PecamKO 
cells. An additional band was appreciated at ~ lOOkD and 1 lOkD, respectively.
Candidate blotting experiments for a number of signaling, adhesion and adaptor proteins 
of these approximate sizes failed to identify the coprecipitating phosphoproteins; in 
particular, neither beta catenin nor VE-cadherin were present in any discernible 
quantitity. Further analysis will likely require direct analysis of the bands through in-gel 
tryptic digests and peptide mass identification.
To determine whether these phosphoproteins are potential targets of SHP-2 
phosphatase activity, SHP-2 was immunoprecipitated in the presence of orthovanadate to 
inhibit tyrosine phosphatase activity. Orthovanadate was then washed out and SHP-2 
allowed to dephosphorylate any co-precipitating phosphoproteins (Figure 33b). SHP-2 
co-precipitated with different major phosphoproteins from PecamKO and PecamRC cells, 
and these phosphoproteins were substrates for the tyrosine phosphatase activity of SHP-2. 
Thus PECAM-1 is instrumental in localizing SHP-2 to a Triton-insoluble fraction in 
endothelial cells, and in directing SHP-2 to specific target phosphoproteins.
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Figure 33: PECAM-1 modulates phosphoprotein association of SHP-2.
A. SHP-2 coprecipitates major phosphoproteins of apparent MW ~ 125kD and 140kD in 
PecamRC and PecamKO endothelial cells, respectively.
B. Immunocomplex phosphatase assay: SHP-2 was IPed, dephosphorylation was allowed 
to proceed for 0 or 20 min and coprecipitates were immunoblotted for PY. (*SHP-2)
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PECAM-1 ITEM signaling slows endothelial migration
To assess the role of PECAM-1 ITIM tyrosine phosphorylation in endothelial 
wound healing migration, PecamRC endothelial cells were transiently transfected with 
either wildtype PECAM-1 (PEC) or with PECAM-1 mutated in its ITIM domain (PEC 
2F). Interestingly, PEC transfection slowed and PEC 2F transfection increased wound 
healing migration (Figure 34a). Thus the functional PECAM-1 ITIM domain, and its 
associated SHP-2, acts in a dose-dependent manner to retard migration. The ITIM- 
deficient PECAM-1 construct appears to act as a dominant negative, increasing wound 
healing migration in PECAM-expressing endothelial cells. It is not the case that a global 
increase in SHP-2 activity due to PECAM-ITIM-mediated activation retards migration.
In fact, overexpression of wildtype SHP-2 increases wound healing migration, whereas a 
loss of function SHP-2 mutant (C459S) slows migration (Figure 34b). SHP-2 mutated 
in its C-terminal SH2 domain to prevent phosphotyrosine engagement, [R138K, (Pluskey 
et al., 1995)], proved to be equally effective in increasing endothelial migration as was 
wildtype SHP-2. Thus the positive role of SHP-2 in increasing endothelial wound 
healing is unlikely to be regulated by ITIM-bearing proteins such as PECAM-1. The role 
of PECAM-1 ITIM-associated SHP-2 activity in wound healing migration on the other 
hand appears to be that of a negative modulator.
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ITIM signaling modulates beta catenin and FAK phosphorylation
Decreased ITIM phosphorylation and thus lower PECAM-1-mediated SHP-2 
tyrosine phosphatase activation should lead to decreased dephosphoiylation of SHP-2 
targets. Adherens junction component beta catenin dissociates from the actin 
cytoskeleton when tyrosine phosphorylated, as in response to shear stress (Ukropec et al., 
2002). Immunoprecipitation revealed significantly increased beta catenin tyrosine 
phosphorylation in PEC 2F transfected endothelial cells (Figure 35a). Focal adhesion 
kinase (FAK) is a target of SHP-2 (Yu et al., 1998); FAK kinase activity in turn is 
required for endothelial cell migration (Gilmore and Romer, 1996). Western blotting 
with phosphospecific antibodies for the src-activating autophosphorylated tyrosine 397 of 
FAK (Eide et al., 1995) revealed increased FAK PY 397 in PEC 2F transfected 
endothelial cells (Figure 35b), pointing to a potential role for PECAM-1 in modulating 
focal contact turnover.
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Figure 34: Role of Pecam ITIM domain in wound healing migration.
A. PecamRC cells were transiently transfected with wildtype (PEC) or ITIM defective 
(PEC 2F) PECAM-1. (n = 8, *p < 0.01).
B. PecamRC cells were transiently transfected with wildtype (SHP2), loss of function 
(C/S), or C-SH2 domain binding defective (R138K) SHP-2. (n = 4, p < 0.05)
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Figure 35: Targets for ITIM-mediated dephosphorylation.
A. Immunoprecipitation of beta catenin reveals significantly increased PY with PEC 2F 
transfection (n = 4, *p < 0.05).
B. Western blotting reveals increased FAK PY 397 in PEC2F-transfected cells 
(n = 3, *p < 0.005).
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Discussion
The role of PECAM-1 in coordinated endothelial cell behaviors appears 
paradoxical. As a whole, PECAM-1 plays a positive role in migration and angiogenesis 
(Cao et al., 2002; DeLisser et al., 1997). Yet expression of ITIM-defective PECAM-1 
increases migration in bovine aortic endothelial cells (Kim et al., 1998), implying a 
negative reguiatory role for PECAM-1 signaling in coordinated motility. Restoration of 
wound healing migration to PecamKO endothelial cells by PECAM-1 is independent of 
signaling via the ITIM domain (Gratzinger et al., 2003b). In PecamRC endothelial cells, 
on the other hand, expression of ITIM-functional PECAM-1 slows and ITIM-defective 
PECAM-1 speeds wound healing migration. Thus PECAM-1 is required at baseline to 
support migration, while ITIM-mediated signaling provides a damp or brake to modulate 
that migration.
In migrating endothelial cells, loss of cell-cell contacts releases PECAM-1 from 
the homophilic engagement that supports tyrosine phosphorylation and recruitment of 
SHP-2 (Bird et al., 1999). Accordingly, we observed a diffuse relocalization of both 
PECAM-1 and SHP-2 and a decrease in overall tyrosine phosphorylation and SHP-2 
association with immunoprecipitated PECAM-1 in migrating endothelial cells. Using 
phosphospecific antibodies we determined that dephosphorylation was overwhelmingly 
at the second ITIM tyrosine, Y686, rather than Y663.
I assessed the effect of this dephosphorylation event on SHP-2 binding and 
activation in vitro using recombinant SHP-2 and PECAM-1 cytoplasmic domain. Lack 
of phosphorylation at tyrosine 686 significantly decreased SHP-2 binding, whereas
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phosphotyrosine 663 was dispensable for recruitment. In contrast, phosphotyrosine 686 
did not contribute to SHP-2 activation, whereas PECAM-1 phosphoiylated at tyrosine 
663 activated SHP-2 as well as did fully phosphoiylated PECAM-1. Engagement of the 
N-SH2 domain of SHP-2 allosterically disinhibits the phosphatase active site (Baiford 
and Neel, 1998). Interestingly, Biacore experiments using PECAM-1 ITIM 
phosphopeptides have indicated that it is phosphotyrosine 663 that engages the N-SH2 
domain (Jackson et ai., 1997), consistent with a model of activation of PECAM-1-bound 
SHP-2 by phosphotyrosine 663.
Given the interaction of SHP-2 with phosphorylated PECAM-1 at cell-cell 
borders, it is plausible that SHP-2 itself may be responsible for the dephosphorylation of 
adjacent PECAM-1 molecules. The remaining ITIM phosphotyrosine 663 could help to 
backpropagate the dephosphorylation signal at the wound edge by sustaining SHP-2 
activity toward adjacent phosphotyrosine 686. Since phosphorylation at tyrosine 686 is 
required to sustain PECAM-1 mediated homophilic cell-cell adhesion (Famiglietti et al.,
1997), dephosphorylation at tyrosine 686 in one endothelial cell could be communicated 
to adjoining cells via decreased PECAM-1 engagement (inside out signaling) and 
consequent loss of phosphorylation at tyrosine 686 in the neighboring cell (outside in 
signaling).
In addition to any potential effects of SHP-2 on PECAM-1 phosphorylation and 
homophilic adhesion, engaged, tyrosyl-phosphorylated PECAM-1 should direct SHP-2 to 
target phosphoproteins involved in maintaining a stable, confluent as opposed to a loose, 
migrating endothelial monolayer. Using detergent-insolubility and sucrose-gradient 
fractionation techniques I determined that SHP-2 is inefficiently targeted to a Triton-
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insoluble, likely cytoskeletal fraction in PECAM-1 deficient endothelial cells. 
Furthermore, SHP-2 associates with and is capable of dephosphorylating an alternate set 
of phosphoproteins in the absence of PECAM-1.
I then transiently transfected endothelial cells with ITIM-defective PECAM-1 
(PEC 2F) to interfere with their dephosphorylation. Beta catenin links adherens junction 
component VE-cadherin to the actin cytoskeleton via alpha catenin; tyrosine 
phosphorylation of beta catenin releases this linkage at the level of the beta catenin/alpha 
catenin interaction (Ukropec et al., 2002). PECAM-1 binds tyrosyl-phosphorylated beta 
catenin (Han et al., 1999); ITIM-regulated SHP-2 activity could thus modulate 
phosphorylation of membrane-associated beta catenin. I found that PEC 2F transfection 
increases overall beta catenin tyrosine phosphorylation without affecting VE cadherin 
association, potentially loosening adherens junction-actin cytoskeletal interactions and 
favoring migration.
Focal adhesion kinase (FAK) activity contributes to endothelial cell migration 
(Gilmore and Romer, 1996) and FAK is a target for SHP-2 phosphatase activity (Yu et 
al., 1998). SHP-2 but not FAK partitioning to the actin cytoskeletal fraction is decreased 
in the absence of PECAM-1; thus PECAM-1 might modulate SHP-2- mediated 
dephosphorylation of FAK. Indeed PEC 2F transfection increased phosphorylation of 
FAK at src-activating tyrosine 397 (Eide et al., 1995); thus phosphorylated PECAM-1 in 
confluent endothelial cells may serve to downregulate FAK activity in the absence of a 
migratory stimulus.
Figure 36 presents a model of PECAM-1 mediated SHP-2 activation at 
confluence and during endothelial migration. In confluent endothelial cells (Figure 36a),
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PECAM-1 is homophilically engaged at cell-cell borders and consequently is tyrosine 
phosphorylated on its ITIM. SHP-2 is engaged via both tyrosines 686 and 663, which 
respectively bind and activate the tyrosine phosphatase. SHP-2 targets proteins at the 
cell-cell junction and within the Triton-insoluble fraction, including beta catenin and 
FAK. Decreased tyrosine phosphorylation of beta catenin at adherens junctions would 
favor alpha catenin association and coupling to the actin cytoskeleton. Decreased FAK 
phosphorylation at tyrosine 397 would lower FAK activity and association of src kinase 
activity, decreasing focal contact turnover necessary for migration.
In wounded, migrating endothelial monolayers (Figure 36b), PECAM-1 is not 
homophilically engaged and becomes dephosphorylated, particularly at tyrosine 686. 
SHP-2 becomes dissociated from PECAM-1, and beta catenin and FAK are no longer 
targeted for dephosphorylation. Increased beta catenin tyrosine phosphorylation 
promotes weakening of adherens junctions and their dissociation from the cytoskeleton. 
Increased FAK activity promotes formation of focal complexes at the leading edge of the 
migrating endothelial cell. Selective dephosphorylation of the PECAM-1 ITIM domain 
appears to play a key regulatory role in coordinated endothelial migration.
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Figure 36: Role of PECAM-1 ITIM in endothelial migration.
Modulation of adherens junction and focal adhesion dynamics via PECAM-1 ITIM 
mediated targetting and activation of SHP-2. See text for discussion.
(6 cat = beta catenin, VE cadh = VE cadherin, Y = tyrosine, P = phosphate)
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Chapter 4: Answers and Questions
Answers
PECAM-1 plays at least two distinct roles in modulating endothelial cell 
migration: in one role, PECAM-1 helps to coordinate Galpha-protein mediated signaling 
to promote Rho-mediated wound healing migration. In the other, the phosphorylated 
PECAM-1 ITIM domain retards wound healing by modulating SHP-2 localization and 
activation. Endothelial expression of PECAM-1 modulates localization of specific 
Galpha protein subunits to caveolin-positive lipid raft subdomains, and hence the 
localized activation state of downstream signaling pathways. Local suppression of 
RhoGTP signaling (Arthur and Burridge, 2001) and activation of FAK, src and ERK 
kinase activity (Pintucci et al., 2002; Rosenfeldt et al., 2001) promotes directed extension 
formation as a component of a coordinated endothelial migratory response to mechanical 
wounding. Global suppression of Rho signaling and activation of Galphai2-mediated 
signaling pathways, on the other hand, promotes exuberant formation of lamellipodial 
extensions and nondirected single cell motility at the expense of coordinated migration.
In addition to and distinct from the overall positive role of PECAM-1 in 
coordinating endothelial wound healing, PECAM-1 ITIM-mediated signaling negatively 
modulates the wound healing response. Failure of developmental stage specific 
dephosphorylation of PECAM-1 ITIM tyrosine 686 in glucose-treated yolk sac 
vasculature, for example, (Pinter et al., 1999) would be expected to interfere with 
coordinated endothelial migration. It may thus partly explain the consequent faulty
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vasculogenesis that results in ectatic vessels, with failure to progress from the primary 
capillary plexus stage to a serially branching mature vasculature. The PECAM-1 ITIM is 
maximally phosphorylated in confluent as opposed to migrating endothelial cells (Lu et 
al., 1996). In this situation SHP-2 is activated at cell-cell junctions in a cytoskeletally 
associated fraction, maintaining low baseline levels of tyrosine phosphorylation of 
adherens junction and focal adhesion components. Stimuli such as mechanical wounding 
(M. Barreuther, unpublished data) and integrin engagement (Lu et al., 1996) promote 
dephosphorylation of the PECAM-1 ITIM, particularly at the second ITIM tyrosine 
which predominantly promotes SHP-2 binding. Increased phosphorylation of beta 
catenin and FAK then promotes loosening of cell-cell adhesion and extension formation 
at the leading edge of the wound. PECAM-1 is then both a necessary component and a 
modulator of coordinated endothelial migration.
ITIM signaling questions
Further analysis of PECAM-1 ITIM mediated signaling is complicated by the 
multiple roles played by SHP-2 in proliferative and migratory responses to growth factor 
receptor signaling (Feng, 1999). Manipulation of overall cellular tyrosine phosphatase 
activity or even SHP-2 activity is therefore not informative in dissecting this pathway. A 
construct encoding a fusion protein consisting of the extracellular domain of PECAM-1 
fused directly to the constitutively active tyrosine phosphatase domain of SHP-2 (Noda et 
al., 2001) has been made for the purpose of addressing this question. This may yield 
candidate SHP-2 substrate phosphoproteins, although it is unclear that a construct lacking
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the entire cytoplasmic domain would be targeted to the same membrane subdomains as 
full length PECAM-1; additionally, proteins such as beta catenin that associate with the 
PECAM-1 cytoplasmic domain may not be accessible to this construct A construct 
comprising full-length PECAM-1 fused to a substrate-trapping mutant of the SHP-2 
tyrosine phosphatase domain (Flint et al., 1997) may be useful to identify direct targets 
by co-immunoprecipitation.
The role of the PEC AM-1 ITIM in modulating VE-cadherin associated catenin 
phosphorylation and the integrity of vascular adherens junctions remains to be elucidated. 
Is alpha catenin lost from beta catenin-VE cadherin complexes when PECAM-1 ITIM 
signaling is inhibited? Is plakoglobin also a substrate for PECAM-1 ITIM-mediated 
dephosphorylation? Plakoglobin links VE-cadherin to vimentin, a component of the 
intermediate filament cytoskeleton; in wounded endothelial monolayers, it is the first 
component lost from the dissolving adherens junctions in mechanically wounded 
endothelium (Lampugnani et al., 1995). Tyrosine phosphorylation of plakoglobin in 
histamine-stimulated endothelium is accompanied by loss of coupling of VE cadherin to 
vimentin and thus intermediate filaments (Shasby et al., 2002). Not only may PECAM-1 
ITIM mediated signaling modulate adherens junction stability; PECAM-1 itself binds 
both beta catenin and plakoglobin (Ilan et al., 2000), and may itself be coupled to the 
actin and/or intermediate filament cytoskeleton. The potential modulation of PECAM-1 
and/or VE-cadherin-vimentin coupling via the phosphorylated ITIM domain remains to 
be explored.
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Gaipha/Rho signaling questions
The evaluation of PECAM-1 modulation of heterotrimeric G protein and Rho 
signaling pathway activities presented above has been performed using confluent 
endothelial cells. These data evaluate signaling while cells are in a steady state, rather 
than in reaction to some physiologic stimulus. In reality migration involves transient, 
spatially appropriate activation of signaling pathways, such as the activation of ERK 
signaling in response to FGF-2 at the migrating front of wound-healing endothelial cells 
(Pintucci et al., 2002) and the transient suppression of Rho signaling by pl90RhoGAP at 
the leading edge of a migrating cell upon engagement of alpha5betal integrins (Arthur 
and Burridge, 2001). Raft localization of signaling molecules, including heterotrimeric G 
protein alpha subunits, might also vary temporally both over the course of migration and 
in response to specific chemotactic stimuli. It will be worthwhile to explore the kinetics 
of signaling pathway activation in PECAM-1 deficient as compared to PECAM-1 
expressing endothelial cells.
Much work remains to be done to elucidate the precise mechanisms of PECAM- 
1-mediated coordination of Galpha signaling. Is the observed decrease in RhoGTP levels 
in PECAM-1 deficient endothelium due only to increased pl90RhoGAP tyrosine 
phosphorylation secondary to promiscuous activation of src via Galphai2, or is it also 
mediated by decreased activation of PDZRhoGEF by Galphal3 (Fukuhara et al., 1999)? 
Does PECAM-1 modulate raft recruitment of Galpha subunits directly, or through effects 
on Galpha interacting proteins? Both cadherins and catenins have been found to localize 
to caveolin positive rafts (Galbiati et al., 2000). Active, GTP-bound Galphal3 competes
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with beta catenin for VE cadherin binding (Meigs et al., 2001); competition by PECAM- 
1 for beta catenin association could free VE cadherin to associate with activated 
Galphal3, promoting the exchange of GDP for GTP and activating Rho signaling. 
Caveolin-1 association inhibits Galpha subunit GTP loading (Li et al., 1995) and 
consequently of downstream signaling. Does PECAM-1 modulate not only targeting to 
lipid rafts, but also caveolin-1 association, of Galpha subunits?
The role of PECAM-1 in properly transmitting SIP mediated signaling 
information may hold clues to the known phenotypes of the PECAM-1 knockout mouse. 
Is the defect in angiogenesis during the chronic phase of foreign body inflammation 
secondary to deficient SIP mediated signaling? In vitro tube formation assays, as well as 
in v/vo assays of angiogenesis using pellets impregnated with SIP alone or in 
combination with other growth factors, may help to address this question.
The possible role of PECAM-1 mediated Rho signaling in transmitting the 
inhibitory of effect of high glucose on single cell motility of transforming endocardial 
cushion cells has already been discussed. Further clarification is needed of the signaling 
pathways involved in the endocardial cushion system. Experiments to confirm the 
protective role of Rho inhibition are under way in this system. Further work will explore 
the role of VEGF-mediated Rac activation in mediating migration of transforming 
endocardial cells over the collagen I gel (see Figure 15b). Treatment with N- 
acetylcysteine to block Rac mediated production of H2O2 should disinhibit low molecular 
weight PTPase. The dephosphorylation of pl90RhoGAP would be expected block local 
inhibition of Rho signaling, and should therefore block endocardial cell motility even in 
the presence of supplemental VEGF.
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SIP increases transendothelial resistance, a measure of vascular junctional 
integrity, in a pertussis-inhibitable, Rho-dependent manner (Garcia et al., 2001). 
PECAM-1 null endothelium exhibits prolonged permeability in response to histamine, 
and transmigration of T cells is enhanced across PECAM-1 null endothelium. This 
vascular defect may in part contribute to the susceptibility of PECAM-1 null mice to 
invasion of their central nervous system by leukocytes as a part of the pathogenesis of a 
mouse model of multiple sclerosis (Graesser et al., 2002). Is this due in part to the 
decreased responsiveness of the PECAM-1 deficient vasculature to the serum-derived 
sphingolipids that promote the reestablishment of tight vascular junctions? In vitro 
testing of SIP-mediated increases of transendothelial resistance of PECAM-1 deficient 
versus wildtype vasculature could address this question.
Similarly, the bleeding time defect of PECAM-1 null mice is attributable to the 
vasculature rather than to bone marrow derived components (Mahooti et al., 2000). High 
concentrations of SIP are released from platelets during clotting, but successful stanching 
of bleeding involves more than just platelet activation and thrombosis. The subjacent 
endothelium must also contract to reveal the underlying thrombogenic collagen surface in 
response to platelet-released factors such as thrombin (Cotran et al., 1994). Thrombin 
mediates endothelial cell contraction through RhoGTP-mediated activation of 
pl60ROCK, myosin light chain kinase, and consequently actin-myosin mediated 
contractility (Essler et al., 1998). In the context of inflammation, histamine likewise 
promotes a pl60ROCK-mediated increase in endothelial permeability (Wojciak-Stothard 
et al., 2001). Preliminary studies indicate that both thrombin and histamine activate Rho
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to a significantly lower extent in PECAM-1 null as opposed to PECAM-1 reconstituted 
endothelial cells (data not shown).
The thrombin receptor belongs to the seven-transmembrane heterotrimeric G 
protein linked family of protease activated receptors (PARs) and promotes endothelial 
cell migration and angiogenesis through pathways involving Rho signaling downstream 
of Galphal3 (Maragoudakis et al., 2002; Richard et al., 2001). Histamine receptor 
subtype HI, which promotes vascular permeability, is also a seven transmembrane 
receptor, although unlike the thrombin receptor it is ligand activated and primarily signals 
through Galphaq/11 (Leurs et al., 1995). Thus the role of PECAM-1 in modulating SIP 
mediated wound healing migration may extend to modulation of signaling via Galpha 
subunits downstream of multiple seven transmembrane receptors. Importantly, CXCRs, 
seven-transmembrane receptors for cysteine-x-cysteine motif containing chemokines 
including SDF-1 (CXCR4) (Salvucci et al., 2002) and interleukin-8 related cytokines 
(CXCR1/2) (Belperio et al., 2000), play an important role in angiogenesis in the settings 
of injury, inflammation and neoplasia. Further pursuit of the signaling pathways and 
(patho)physiologic sequelae of PECAM-1 expression should prove fruitful for years to 
come.
In vitro migration assays: how should they be interpreted?
Nondirected single cell motility, or chemokinesis, represents an increase in cell 
movement in response to serum or cell derived growth factors; angiogenic growth factors
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such as VEGF and SIP induce not only an increase in this baseline cell movement, but 
directional motility with respect to a concentration gradient (chemotaxis if the gradient is 
in the liquid phase, haptotaxis if it is fixed to cell surfaces or to extracellular matrix). 
Most developmental or physiologic cell movements in vivo occur in a directional maimer 
in response to some chemotactic or haptotactic cue, with a balance between the degree of 
increase in baseline cell motility and the degree to which that motility is strictly 
directional. At one end of the spectrum of in vivo correlates to chemokinesis as opposed 
to chemotaxis, for example, lies hepatocyte growth factor (HGF). HGF induces 
scattering motility in vitro through activation of the Met tyrosine kinase receptor and 
promotes the dissemination and invasive behavior of malignant carcinoma cells in 
response to autocrine signaling (Danilkovitch-Miagkova and Zbar, 2002). At the 
opposite end of the random versus directed single cell motility spectrum, neuronal cell 
migration in vivo is exquisitely directionally guided through a combination of 
chemotactic and haptotactic cues which tightly control Rho and Rac activation and hence 
directional motility (Park et al., 2002b).
Coordinated wound healing migration necessarily involves directional movement, 
as the wounding induces release of chemotactic factors at the leading edge and uncovers 
haptotactic factors previously laid down by the endothelial monolayer. For example, 
injury induces endothelial release of fibroblast growth factor-2 (FGF-2), which 
contributes to the endothelial wound healing response in vitro (Pintucci et al., 2002; 
Santiago et al., 1999). In vivo, denuded basement membrane promotes platelet 
aggregation and release of multiple chemotactic factors including SIP, which also 
promotes endothelial wound healing migration (Lee et al., 2000a). Finally, exposed
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extracellular matrix components such as fibronectin themselves provide strong 
haptotactic cues to endothelial wound healing and angiogenesis (Kim et al., 2000). 
PECAM-1 deficient endothelial cells perform poorly in the wound healing assay in vitro 
and in vivo demonstrate poor angiogenesis during the chronic phase of foreign body 
inflammation (Solowiej et al., 2002).
Although the single cell motility of PECAM-1 deficient endothelial cells is 
dramatically increased with respect to PECAM-1 expressing cells, I would predict that 
these cells would respond weakly if at all to a directional signal in assays of single cell 
chemotaxis or haptotaxis. Indeed, I believe that the very property that allows these cells 
to form multiple extensions and initiate motility in the absence of a directional signal, 
their low level o f RhoGTP signaling at baseline, would perforce lower their sensitivity to 
inputs that modulate directionality by transiently decreasing Rho signaling to allow for 
extension formation at the leading edge (see Fig 15b). Thus, for example, a Transwell™ 
single cell motility assay of chemotaxis toward VEGF might reveal the same or even a 
greater number of transmigrated PecamKO than PecamRC cells due to the chemokinetic 
advantage of PecamKO cells; however the increase in transmigration with the addition of 
VEGF to the bottom well would be expected to be dramatically greater in the case of the 
PecamRC cells.
Does PECAM-1 signaling modulation have any real-world applicability?
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A thorough understanding of the mechanics of PEC AM-mediated modulation of 
heterotrimeric G-protein mediated signaling in endothelial cells may yield viable tools 
not only for the benchtop researcher but for the modulation of epidemiologically 
important aspects of cardiovascular pathology. For example, PECAM-1 knockout mice 
have significant defects in reestablishment of cell-cell junctional integrity following a 
stimulus that increases permeability. Histamine induces a transient increase in 
endothelial permeability; the duration of increased permeability is several times longer in 
brain and dermal vasculature of PECAM-1 knockout mice and in PecamKO endothelial 
cells in vitro (Graesser et al., 2002). This failure to reestablish cell-cell junctions 
following what should be a transient increase in permeability may likewise underlie the 
increased transmigration of T lymphocytes (Graesser et al., 2002) as well as 
polymorphonuclear neutrophils (Solowiej et al., 2002) across PECAM-1 negative 
endothelia. Further experiments will be required to determine how much of this defect is 
due to a failure to dephosphoiylate beta catenin, and thus to reassemble stable actin 
cytoskeleton-linked adherens junctions, due to a lack of PECAM-1 ITTM-mediated SHP- 
2 activity at cell-cell borders. Stable transfectants of PecamKO endothelial cells 
expressing ITIM-defective, full-length PECAM-1 should prove informative in this 
regard. Therapeutic modulation of PECAM-1 ITIM phosphorylation may be achievable 
with carefully developed anti-PEC AM-1 antibodies or recombinant portions of the 
PECAM-1 ectodomain.
Increased endothelial permeability contributes to the pathogenesis of a variety 
major causes of morbidity and mortality such as atherosclerosis, chronic inflammation, 
diabetic retinopathy, and sepsis. Heterotrimeric G protein mediated signaling and
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modulation of Rho activation through Galphal2/13 and Galphaq/11 (Sah et al., 2000) is 
prominently involved in modulating endothelial permeability (van Nieuw Amerongen 
and van Hinsbergh, 2001). The histamine receptors for example are G-protein coupled 
seven transmembrane receptors (Leurs et al., 1995); the major receptor subtype involved 
in modulating vascular permeability, HI, is linked to Galphaq/11. Thrombin signals 
through Galphal2/13 to mediate Rho signaling and increased vascular permeability as 
well as angiogenesis (Richard et ai., 2001). Lipophosphatidic acid (LPA), a product of 
low density lipoprotein (LDL) oxidation present in atherosclerotic plaques (Siess et al.,
1999), likewise stimulates endothelial cell permeability through heterotrimeric G protein 
mediated modulation of Rho signaling. Sphingosine-1-phosphate, on the other hand, 
promotes vascular maturation and decreased permeability through Edg-receptor 
dependent signaling, including Rho activation (Garcia et al., 2001). It seems likely that 
precise modulation of the timing, duration and localization of Rho signaling by 
heterotrimeric G proteins is required to maintain a stable rather than a dysfunctional, 
leaky vasculature. Since PECAM-1 appears to be capable of modulating the localization 
of specific Galpha protein subunits to membrane microdomains, an analysis of the 
particular region of the PECAM-1 cytoplasmic domain responsible for this localization 
could prove to be quite valuable. Should an oligopeptide be found that is capable of 
influencing the localization and thus the signaling properties of specific Galpha subunits, 
its delivery to dysfunctional vascular beds may prove to be useful in modulating the 
responsiveness of endothelia to permeability-inducing or atherogenic stimuli.
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Chapter 5: Materials and Methods
Antibodies
Rabbit polyclonal antibody to murine PECAM-1 extracellular domain (Sleet), 
human PECAM-1 cytoplasmic domain (BooBoo), and to PECAM-1 ITIM 
phosphotyrosines 663 or 686 (Lu et al., 1996; Pinter et al., 1997) were generated in our 
laboratory and have been previously described. Monoclonal antibodies to extracellular 
signal regulated kinase 2 (ERK2), phosphotyrosine, and SHP-2 and polyclonal antibody 
to caveolin and paxillin phosphotyrosine 118 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Monoclonal antibodies to beta catenin, Racl, Rho and 
focal adhesion kinase (FAK) and polyclonal antibodies to heterotrimeric G protein 
subunits Galphai2 and Galphal3 were purchased from Transduction Laboratories (San 
Diego, CA). Monoclonal antibodies to RhoGAP (Guanosine triphosphate Phosphatase 
Activating Protein) p i90 and polyclonal antibodies to FAK phosphotyrosine 397 and 
RasGAP pl20 were purchased from Upstate Biotechnologies (Lake Placid, NY). Anti- 
phosphothreonine/tyrosine ERK polyclonal antibody was purchased from Cell Signaling 
Technology (Beverly, MA). Monoclonal antibody to beta actin was purchased from 
Sigma-Aldrich (St. Louis, MO). Monoclonal hamster antibody against murine PECAM- 
1, and monoclonal rat antibody against murine vascular endothelial cadherin, for 
fluorescence activated cell sorting (FACS) analysis were purchased from PharMingen 
(San Diego, California, USA).
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Reagents
Rhodamine-phalloidin and methyl beta cyclodextrin was purchased from Sigma- 
Aldrich (St. Louis, MO). C. botulinum exoenzyme C3 (exo C3), pertussis toxin (PTX), 
sphingosine-1 -phosphate (SIP) and Y27632 were purchased from Calbiochem- 
Novabiochem (San Diego, CA). Complete Protease Inhibitor™ (CPI) was purchased 
from Roche Diagnostics (Mannheim, Germany). Polypeptides, both phosphorylated and 
nonphosphorylated, were synthesized by the Howard Hughes Medical Institute-Keck 
Foundation Lab at Yale University. Sequences were: for the PECAM-1 ITIM tyrosine 
663 sequence, PLN SDV QY (phospho) T EYQ VSS; and for the tyrosine 686 sequence, 
KKD TET VY (phospho) S EVR KAV.
Constructs
Full-length human PECAM-1 in the mammalian expression vector pAPEX-1 
(Alexion, New Haven, CT) and its Y663F mutant have been described (Lu et al., 1996). 
An additional mutation at Y686F was made using the QuikChange™ Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions 
to produce an ITIM-defective construct. A myc-tagged truncated construct in pAPEX-1 
lacks most of the ectodomain (Kim et al., 1998). The PECAM-1 cytoplasmic domain in a 
glutathione-S-transferase (GST) fusion protein expression construct (pGEX2T, 
Pharmacia, Piscataway NJ) (Lu et al., 1997) was also mutated at Y686F and at Y663F.
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pGEX2T-SHP-2 construct was a gift o f H. Ohnishi et aL(Ohnisbi et al., 1996); a 
phosphatase-dead mutant (D425A) (Flint et al., 1997) was made using site-directed 
mutagenesis.
The Rho binding domain of Rhotekin in pGEX2T (Pharmacia) was a gift of X.D. 
Ren and M.A. Schwartz (Ren and Schwartz, 2000). A GST-fusion protein expression 
construct of the Rac binding region of PAK, pGEX4T-l PAK70-106, was a gift of F. 
Giancotti (Mettouchi et ai., 2001).
Myc-tagged SHP-2 and SHP-2 loss of function mutant C459S in pIRES-EGFP 
(Clontech, Palo Alto, CA) were a gift of M. Kontaridis and A. Bennett. An SHP-2 
mutant incapable of engaging its C-terminal SH2 domain (R138K) (Pluskey et al., 1995) 
was made by site-directed mutagenesis. pCDNA3-VCAM mammalian expression 
construct was made by subcloning the full-length cDNA purchased from Biogen 
(Cambridge, MA).
Oligonucleotides
PECAM-1 antisense oligonucleotides: 5’ TCC TTC CAG GGA TGT GAT C 3’ 
for human PECAM-1 and control scrambled oligonucleotide 5’ TTC TAC CTC GCG 
CGA TTT AC 3’ were gift of T. Condon at Isis™ Pharmaceuticals (Carlsbad, CA).
Mutagenic primers were: for PECAM-1 Y686F, 5’ GGA CAC AGA GAC AGT 
G IC  AGT GAA GTC CGG 3’ and its inverse; for PECAM-1 Y663F, 5’ CCT CTG AAC 
TCA GAC GTG CAG TTC ACG GAA GTT CAA GTG TCC 3’ and its inverse; for 
SHP-2 D425A, 5’ GGA CCT GGC CAG CCC ATG GCG TGC C 3’ and its inverse; for
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SHP-2 R138K, 5’ CAT GGT AGT TTT CTT GTA AAA GAG AGC CAG AGC CAC 
CCT GG 3’ and its inverse.
Cell culture
Endothelioma cell line luEnd.PECAM-1.1 (PecamKO) was established by 
retroviral transduction of primary endothelial cell culture with the polyoma virus middle 
T-oncogene (Wagner and Risau, 1994; Wong et al., 2000). PecamKO cells retrovirally 
transduced with full-length murine PECAM-1 cDNA to generate a PecamRC 
(reconstituted) cell line (Graesser et al., 2002; Wong et al., 2000). Cells were cultured in 
luEnd media [Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 10 mM HEPES pH 7.4,1% L-glutamine, 1% nonessential 
amino acids, 1% pyruvate, 10,000 U/ml penicillin/ streptomycin, and 105M 2- 
mercaptoethanol (GIBCO BRL)] and incubated at 37°C in 8% CO2. Selection of 
PECAM-1 expression on PecamRC cells was maintained with 1 pg/ml puromycin.
Human umbilical vein endothelial cells (HUVEC) were purchased from the Boyer 
Center for Molecular Medicine Cell Culture Core (Yale Medical School) and were 
cultured on gelatin in Ml 99 medium (Life Technologies) supplemented with 20% heat- 
inactivated FBS, 50 mg/ml endothelial cell growth supplement, 50 mg/ml heparin, 10 
mM HEPES, 2 mM L-glutamine and antibiotics. Bovine aortic endothelial cells 
(BAECs) were cultured as previously described (Madri et al., 1988). 
Hemangioendothelioma (Eoma) cells were obtained from Robert Auerbach (University of
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Wisconsin, Madison, WI) and were grown in complete DMEM supplemented with 10% 
FBS and antibiotics (Obeso et al., 1990).
Immunostaining
Cells were incubated overnight on 8-chamber glass culture slides (Falcon, 
Becton-Dickinson) that had been coated with fibronectin. Cells were fixed in Streck's 
Tissue Fixative (STF, Streck Laboratories, La Vista, NE), permeabilized with 0.5% 
Triton X-100 in TBS, and stained with rhodamine-phalloidin 1:200, anti-phosphopaxillin 
1:500, anti-PECAM-1 1:100 or anti-SHP-2 1:100 followed by fluorescein or rhodamine- 
conjugated secondary (Jackson Immunoresearch Labs, West Grove, Pennsylvania) at 
1:200. After coverslipping with Antifade Mounting Media (Molecular Probes, Eugene, 
OR) cells were photographed using a Carl Zeiss Research microscope (Gottingen, 
Germany) and SPOT digital camera (Diagnostic Instruments Inc, Sterling Heights, 
Michigan).
Transient transfections
Subconfluent PecamKO or PecamRC endothelial cells were transfected using 
LipofectAMINE2000, Life Technologies (Grand Island, NY) according to the 
manufacturer’s instructions. Briefly, cells were split 1:3 into 100 mm tissue culture 
plastic dishes and cultured overnight. When they had reached 70-80% confluence they
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were transfected using 1 jig pIRES EGFP + 9 pg test DNA and 30 pi transfection 
reagent. Expression was assessed using green fluorescence at 24 hours.
For antisense oligonucleotide transfections, passage three HUVEC at 70-80% 
confluence were transfected using Lipofectin (Life Technologies) according to the 
manufacturer’s instructions. PECAM-1 expression was assessed by western blotting at 
24 or 48 hours by western blot.
Nondirected motility assay
8 pm pore size Transwells® (Coming Inc. Coming, NY) were coated overnight 
with 12.5 pg/ml fibronectin (Madri et al., 1988) or type I collagen (Haas et al., 1998) and 
blocked with 5% BSA as described. 100 pL of media was added to the top well and 500 
pL to the bottom well. Endothelial cells were briefly trypsinized, washed twice in 
endothelial media, and 100 pL of a 106 cell/ml single cell suspension was added to the 
top well. Lung endothelial cell transmigrations were done in luEnd media. HUVEC 
transmigrations were done in HUVEC media lacking endothelial cell growth supplement 
and with FBS decreased to 2%. After 2.5 hours of incubation at 37°C in 8% CO2 the 
cells were fixed in STF, and stained with crystal violet. Cells on top of the filter were 
removed with a cotton swab and cells on the bottom surface were quantitated as number 
of cells transmigrated per high power field (20x objective, corresponding to an area of 
approximately 5mm2).
Wound healing assay 
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60 mm Falcon® petri dishes (Becton Dickinson, Franklin Lakes NJ) were coated 
with fibronectin as above. Butanol-extracted fibronectin and BSA were used for 
experiments involving SIP. Confluent PecamKO and PecamRC monolayers grown on 
fibronectin-coated plates were scraped with a 15-well minigel comb leaving concentric 
rings of cells, washed with PBS, and incubated 24 hours. HUVEC wound healing 
migrations were on gelatin-coated plates. For SIP experiments, CS-FBS was prepared by 
incubating 50 mL FBS with 5 g activated charcoal (Sigma) overnight at 4°C (Lee et al.,
1998). The CS-FBS was centrifuged (10 min at lOOOg) and filtered through a 0.22 pm 
sterile Nalgene® filter (Sybron Corp, Rochester NY). Distance migrated was quantitated 
by taking pictures at 0 and 24 hours with a Nikon Coolpix995 Digital Camera (Nikon 
Corp., Tokyo Japan) on an Olympus IM light microscope (Melville, NY) and measuring 
distance of wound edge from a mark on the bottom of the plate.
Quantitation of extension formation
104 cells/well were plated in a fibronectin-coated 24-well plate. Cells were fixed 
in STF and stained with crystal violet, photographed as above, and quantitated using the 
public domain NIH Image program (National Institutes of Health) to determine perimeter 
and cell area. The theoretical radius (r) had the cell been a perfect circle was determined 
according the formula r^meier = perimeter/27t and rarea= V(area/7t), and the ratio rpenmeter to 
Tarea was used to determine deviation from circularity.
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Western blotting
Confluent monolayers of PecamRC and PecamKO cells were washed twice in 
ice-cold PBS containing 1 mM orthovanadate, and scraped into lysis buffer (20 mM Tris 
pH 7.5,100 mM NaCl, 10 mM EDTA, 1% Nonidet P-40,1% deoxycholate, 0.1% SDS,
50 mM sodium fluoride, 1 mM sodium orthovanadate, and CPI). Wound-healing BAECs 
were lysed in 200 pi [50 mM Tris, pH 7.4,100 mM NaCl, 0.5 % Triton X-100, 0.5 % 
sodium deoxycholate, a protease cocktail (CPI, Boehringer-Mannheim) and 0.2 mM 
ortho vanadate]. Lysates were centrifuged at 14,000# at 4 °C for 10 minutes, and 
supernatant protein concentration was determined using the Bio-Rad Protein Assay (Bio- 
Rad Laboratories, Hercules, CA) as directed. 20 pg protein were boiled with 4x sample 
buffer (240 mM Tris pH 6.8,40% glycerol, 8% SDS, 0.002% bromophenol blue, 0.002% 
B-mercaptoethanol).
Samples were separated by SDS PAGE, transferred to an Immobilon P 
membrane, (Millipore, Bedford, MA), probed with anti-ERK 1:10,000, anti-phosphoERK 
1:1000, anti-FAK 1:10,000 and anti-FAK PY397 1:2000, followed by horseradish 
peroxidase conjugated goat anti-mouse or anti-rabbit IgG, (Promega, Madison, WI) and 
developed using Chemiluminescent Reagent Plus (PerkinElmer Life Sciences, Boston, 
MA). Blots were scanned on an Arcus II scanner (Agfa, Mortsel, Belgium) and 
quantitated using BioMax ID software (Kodak, Rochester, NY).
Immunoprecipitation
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200 pg protein were pre-cleared with protein A/G-Sepharose (Santa Cruz); the 
cleared supernatant was incubated with the appropriate antibody for one to two hours 
turning end-over-end at 4°C, then precipitated with A/G-Sepharose. Beads were washed 
three times in lysis buffer and boiled in 4x sample buffer. Samples were separated by 
SDS-PAGE, transferred to an Immobilon P membrane, probed with anti beta catenin 
1:10,000, anti-pl90 RhoGAP 1:5000, anti-pl20 RasGAP 1:5000, anti-SHP-2 or anti- 
phosphotyrosinc 1:10,000, and developed and quantitated as above.
Triton X-100 fractionation
Triton X-100-soluble and insoluble fractions were prepared as described in 
(Rajasekaran et al., 2001). Briefly, cells were scraped into 200 pi lysis buffer (50 mM 
NaCl, 10 mM PIPES pH 6.8,3 mM MgCh, 0.5% Triton X-100,300 mM sucrose, 1 mM 
PMSF, 100 U/ml DNAse) for 10 min at 4°C, then centrifuged at 4°C for 30 min at 
14,000 rpm. Pellet and supernatant fractions were boiled in 4x sample buffer prior to 
separation by SDS-PAGE, immunoblotting, and probing with anti-beta actin 1:10,000, 
anti-FAK 1:10,000, or anti-SHP-2.
Raft fractionation
Sucrose density gradient lipid raft fractionation was carried out in a 
detergent-free sodium bicarbonate buffer essentially as described by (Song et al., 1996). 
Briefly, confluent endothelial cells were scraped into lysis buffer (500 mM sodium
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bicarbonate) and sonicated. 85% sucrose in MBB (25 mM MES, pH 6.5,150 mM NaCl, 
and 250 mM sodium bicarbonate) was added to bring the sample to 42.5% sucrose. The 
two mL sample was placed in an ultracentrifuge tube on ice for 4 hours, then layered with 
8 mL of 30% sucrose in MBB followed by 2 mL 5% sucrose in MBB were layered to 
make a discontinuous gradient.
The sample was centrifuged at 39,000 rpm for 18 hr at 4°C in an SW41 
rotor (Beckman Instruments, Palo Alto, CA), at which time an opalescent band 
representing the caveolin-positive raft fraction was visible at the 30%/5% sucrose 
interface. One mL fractions were carefully pipetted, and 20 pL samples boiled in 4x 
sample buffer for analysis, separated by SDS-PAGE and transferred to an Immobilon P 
filter. Blots were probed with anti-PECAM-1, anti-SHP-2, antiphosphotyrosine, anti- 
caveolin, or anti-beta actin at 1:10,000 or anti-Galphai2 or anti-Galphal3 at 1:250 and 
developed and quantitated as above.
Recombinant protein production
GST-PECAM-1 cytoplasmic domain was expressed in protease deficient BL21 
bacteria (Pharmacia) induced with 0.5 mM isopropyl-fi-D-thiogalactoside (Sigma) for 3 
hours at 37°C. Bacteria were lysed with Bacterial Protein Extraction Reagent (Pierce) 
and Complete Protease Inhibitor (CPI) (Boehringer Mannheim). After spinning 30 min 
at 14,000g at 4°C, the bacterial lysate supernatant was incubated with a 50% slurry of 
glutathione agarose beads (Sigma) to pull out the GST fusion protein, and washed 5 times 
in TBS + 1 mM ethylene diamene tetraacetic acid to eliminate bacterial proteins.
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Tyrosine phosphorylated GST-PECAM-1 was produced as directed in TKX1 bacteria 
(Stratagene) and phosphorylation confirmed by western blotting with phosphospecific 
antibodies to ITIM phosphotyrosines 663 and 686 at 1:5000 as described.
Concentration was determined using a standard curve of bovine serum albumin 
(Pierce) after SDS-polyacrylamide gel electropheresis (PAGE) and Coomassie staining. 
GST-SHP-2 was produced essentially as described (Dechert et al., 1994), but in BL21 
bacteria (Pharmacia) and at 28°C. Thrombin cleavage of recombinant SHP-2 from its 
GST tag was carried out as described (Dechert et al., 1994); concentrations were 
determined as with Bio-Rad Protein Assay (Hercules, CA).
Recombinant SHP-2 pulldowns
10 pg of glutathione-agarose-bound GST-PECAM-1 was combined with 5 pg 
recombinant SHP-2 in 500 pi Pulldown Buffer (50 mM Tris, pH 7.4,100 mM NaCl, 0.5 
% Tween-20,10 mM (3-mercaptoethanol) and rotated for 30 min at 4°C. The glutathione 
agarose beads with bound GST-PECAM-1 and any associated SHP-2 were washed in 
cold Pulldown Buffer. Samples were separated by SDS PAGE, western blotted as 
described, probed with anti-SHP-2 1:10,000 or anti-PECAM-1 1:10,000, and developed 
and quantitated as described.
RhoGTP and RacGTP pulldown assays
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GST-Rho binding domain was expressed and purified using glutathione-agarose 
beads (Sigma-Aldrich) as described (Ren and Schwartz, 2000). GST-p21 Activated 
Kinase (PAK) Rac binding domain was expressed and purified as described (Royal et al.,
2000). Freshly confluent PecamRC or PecamKO cells grown on fibronectin-coated 100 
mm plates were lysed, 20 pL lysate set aside for normalization, and RhoGTP or RacGTP 
pulled down using glutathione-agarose-bound GST-Rho binding domain or GST-PAK 
Rac binding domain as described (Ren and Schwartz, 2000; Royal et al., 2000). Samples 
were separated by SDS PAGE, transferred to an Immobilon P membrane, probed with 
anti-Rho 1:100 or anti-Rac 1:100 and developed and quantitated as above.
Recombinant SHP-2 phosphatase assays
To assess activation of recombinant SHP-2 by GST-PECAM-1,3 pg bead-bound 
GST-PECAM-1 and 2 pg recombinant SHP-2 was suspended in 45 pi Phosphatase 
Buffer (50 mM sodium acetate, pH 5.3,50 mM NaCl, 10 mM dithiothreitol) in 96-well 
plates (Falcon); at t = O’ 5 pi 500 mM /Miitrophenyl phosphate (pNPP) were added and 
the mixture shaken 10 min (adapted from (Ohnishi et al., 1996)). A Wallac Victor 
Multilabel Counter attached to a PC laptop was used to record absorbance at 405 nm.
Immunoprecipitated SHP-2 phosphatase activity
Phosphatase activity of immunoprecipitated SHP-2 was assessed essentially as 
described (Tang et al., 2000). Briefly, cells were treated with pervanadate prior to lysis
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and SHP-2 was immunoprecipitated in the presence of orthovanadate on ice. 
Orthovanadate was washed out to disinhibit phosphatase activity and dephosphorylation 
allowed to proceed for 0 or 20 minutes at 25°C prior to quenching with lOmM 
orthovanadate. Tyrosine phosphorylation of SHP-2-associated proteins was evaluated by 
western blotting.
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